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The Intrinsic Caspase Death Pathway in Stroke Neurodegeneration 
 
Nsikan Enekan Akpan 
 
Stroke has been a major source of morbidity and mortality for centuries. Eight-five 
percent of all strokes are ischemic in nature, meaning they are caused by the occlusion of a major 
cerebral artery. Despite extensive research to develop effective treatments for ischemic stroke, 
therapeutic options remain limited.  
Apoptosis (also termed “programmed cell death”) is a process by which a stressed or 
damaged cell commits “suicide”. In stroke, runaway apoptosis contributes to stroke 
neurodegeneration and neurological decline for days to weeks after disease onset.  
Cysteine-ASPartic proteASEs (caspases) are key mediators of apoptosis that are activated 
in distinct molecular pathways, but their impact in stroke is poorly defined. Direct evidence for 
caspase activation in stroke and the functional relevance of this activity has not been previously 
characterized.  
For this dissertation, we developed an unbiased technique for in vivo trapping of active 
caspases in rodent models of ischemic stroke. We isolated active caspase-9 as a principal 
contributor to ischemic neurodegeneration in rodents (Rattus norvegicus & Mus musculus). 
Caspase-9 is the initiator caspase for   the intrinsic cell death pathway. 
Intranasal delivery of a novel, cell membrane-penetrating inhibitor for caspase-9 
confirmed the pathogenic relevance of caspase-9 activity in stroke. Caspase-9 inhibition 
provided neurofunctional protection and established caspase-6 as its downstream target.  
Caspase-6 is an effector caspase and a member of the intrinsic death pathway that has never been 
implicated in stroke until now.  
  
Coincidentally, we discovered that caspase-6 is specifically activated within the axonal 
compartment. The temporal and spatial pattern of activation demonstrates that neuronal caspase-
9 activity induces caspase-6 activation, which mediates axonal loss in the early stages of stroke 
(<24 hours). We developed a novel inhibitor for caspase-6, based on a catalytically inactive 
clone, which demonstrated neuroprotective and axoprotective efficacy against ischemia. 
Collectively, these results assert that selective inhibition of caspase-9 and caspase-6 is an 
effective translational strategy for stroke.  
The impact of caspase activity is not restricted to neuronal death, as caspases can 
exacerbate inflammation and alter glial function. Thus, caspases are logical therapeutic targets 
for stroke. However, they have never been clinically evaluated due to a paucity of ideal drug 
candidates. This dissertation outlines fresh insights into the mechanisms of stroke 
neurodegeneration and offers novel caspase-based therapeutic strategies for clinical evaluation. 
 i 
TABLE OF CONTENTS 
LIST OF FIGURES .......................................................................................................................v 
LIST OF TABLES ...................................................................................................................... vii 
LIST OF ABBREVIATIONS & ACRONYMS ....................................................................... vii 
ACKNOWLEDGEMENTS ........................................................................................................ xi 
DEDICATION ........................................................................................................................... xiii 
Chapter 1. General Introduction ..................................................................................................1 
1.1.  Stroke Neurodegeneration ...................................................................................................1 
1.1.1.  Disease Criteria ........................................................................................................1 
1.2.  Stroke Therapies ..................................................................................................................5 
1.2.1.  Preventative Measures .............................................................................................6 
1.2.2.  Acute Interventions ..................................................................................................6 
1.2.3.  Neuroprotection: An Argument For Caspase Inhibition ..........................................7 
1.3.  Caspases: A Focused Overview ...........................................................................................9 
1.3.1.  Caspase Classification .............................................................................................9 
1.3.2.  Translational Strategies For Caspase Inhibition ....................................................15 
1.3.3.  CNS Delivery Methods ..........................................................................................20 
1.3.4.  Axon Degeneration, Caspases, and Stroke ............................................................20 
1.4.  Molecular Mechanisms of Cerebral Edema ............................................................... 23 
1.4.1.  Types of Cerebral Edema .......................................................................................23 
1.4.2.  The Blood Brain Barrier and the Neurovascular Unit ...........................................25 
1.4.3.  Proteases Govern BBB Integrity During Ischemia ................................................25 
1.4.4.  Pericytes Contribute To Ischemic Cerebral Edema ...............................................27 
 ii 
1.5.  Significance and Outline ......................................................................................... 28 
Chapter 2. Materials and Methods .............................................................................................29 
2.1.  Rodent Husbandry and Handling .......................................................................................29 
2.1.1. Mouse Breeding .....................................................................................................29 
2.1.2. Transient Middle Cerebral Occlusion (tMCAo) ....................................................29 
2.1.3. Neonate Hypoxia-Ischemia. ...................................................................................30 
2.1.4. Stereotactic Injection .............................................................................................30 
2.1.5. Intranasal Injection .................................................................................................31 
2.1.6. Behavioral Examinations .......................................................................................31 
2.2.  Peptide Inhibitors for Caspases ..........................................................................................33 
2.2.1. Peptides ..................................................................................................................33 
2.2.2. Penetratin1 Linkage ...............................................................................................35 
2.2.3. Rhodamine Labeling of Peptides ...........................................................................35 
2.3.  Biochemical .......................................................................................................................36 
2.3.1. In Vivo Caspase Activity Assay .............................................................................36 
2.3.2. Axon Fractionation ................................................................................................37 
2.3.3. Quantification of Edema by Evans Blue Dye Extravasation  ................................37 
2.4.  Histochemistry ...................................................................................................................38 
2.4.1. Immunofluorescence ..............................................................................................38 
2.4.2. Immunohistochemistry (DAB staining) .................................................................39 
2.4.3. Infarct Volume .......................................................................................................40 
2.4.4. Bielschowsky Staining (Axons) .............................................................................40 
2.5.  Cell culture .........................................................................................................................40 
 iii 
2.5.1. Hippocampal and Cortical Neurons .......................................................................40 
2.5.2. Neuronal Survival Assays ......................................................................................41 
2.6.  Materials ............................................................................................................................42 
2.6.1. Antibodies ..............................................................................................................42 
Chapter 3. Initiator Caspases in Stroke Neurodegeneration ...................................................43 
3.1. Introduction ........................................................................................................................43 
3.2. Results ................................................................................................................................45 
3.2.1. Measuring Initiator Caspase Activity In Vivo ........................................................45 
3.2.2. Temporal Activation Of Caspase-9 In Cerebral Ischemia .....................................47 
3.2.3. Caspase-9 Inhibitor: Penetratin1-X-linked Inhibitor Of Apoptosis Protein-BIR3 
Domain (Pen1-XBIR3) ....................................................................................................47 
3.2.4. Proneurotrophins, Caspase-9, And Cerebral Edema ..............................................52 
3.2.5. Caspase-8 In Neonatal Hypoxia-Ischemia .............................................................57 
3.3. Discussion ..........................................................................................................................60 
Chapter 4. Effector Caspases in Stroke Neurodegeneration ...................................................65 
4.1. Introduction ........................................................................................................................65 
4.2. Results ................................................................................................................................66 
4.2.1. Caspase-6 Is Active In Neuronal Processes And Soma Following Stroke ............66 
4.2.2. Caspase-3 And Neuronal Cell Type Specification ................................................69 
4.2.3. Caspase-6 Is Enriched In Myelinated Axons .........................................................71 
4.2.4. Genetic Knockout Of Caspase-6 Is Neuroprotective .............................................72 
4.2.5. Caspase-6 Is Activated In Human Stroke ..............................................................75 
4.2.6. Caspase-9 Activates Caspase-6 During Ischemia ..................................................75 
 iv 
4.3. Discussion ............................................................................................................. 79 
Chapter 5. Developing A Caspase-6 Inhibitor ..........................................................................83 
5.1. Introduction ........................................................................................................................83 
5.2. Results ................................................................................................................................84 
5.2.1. Use In Neuronal Cultures Models of Cell Death ...................................................84 
5.2.2. Use In Cerebral Ischemia .......................................................................................87 
5.2.3. Use In Optical Nerve Crush ...................................................................................90 
5.3. Discussion ..........................................................................................................................91 
Chapter 6. Benchmarks: Conclusions and Future Directions .................................................93 
6.1. Surveillance Strategy For in vivo Caspase Activity ...........................................................93 
6.1.1. Benchmark 1: In vivo Active Caspase Precipitation ..............................................93 
6.1.2. Benchmark 2: Innovations For Intracellular Peptide Delivery To The CNS .........95 
6.2. Caspase Biology .................................................................................................................96 
6.2.1. Benchmark 1: The Intrinsic Caspase Pathway In Ischemic Neurodegeneration ...96 
6.2.2. Benchmark 2: The Intrinsic Caspase Pathway In Ischemic Edema .......................97 
6.2.3. Benchmark 3: Axon Compartmentalization Of Caspase-6 Activity ......................98 
6.3. Closing Statement ..............................................................................................................99 
Bibliography ................................................................................................................................100 
Appendices. Detailed Protocols ...................................................................................................117 
I. Cell Lysis Buffers ....................................................................................................117 
II. Active Caspase Precipitation ...................................................................................118 
III. Axon Flotation .........................................................................................................122 
 v 
LIST OF FIGURES 
Chapter 1 
 
Figure 1-1. Major Cerebral Blood Vessels .....................................................................................1 
Figure 1-2. Oxfordshire Community Stroke Project [OCSP] Classification and Stroke  
Syndromes........................................................................................................................................3 
Figure 1-3. Mammalian caspases implicated in stroke .................................................................11  
Figure 1-4. Mechanisms of caspase activation .............................................................................14  
 
Chapter 3 
Figure 3-1. Active caspase-9 is induced by tMCAo .....................................................................46  
Figure 3-2. Caspase-9 and cleaved caspase-6 are induced in the same cells early in tMCAo .....48  
Figure 3-3. Penetratin1 - A Trojan Carrier Peptide for Caspase Inhibitors ..................................49  
Figure 3-4. Delivery of Pen1-fluorescent peptide to CNS by CED ..............................................50  
Figure 3-5. Intranasal application delivers Pen1-XBIR3 throughout the rat CNS .......................52  
Figure 3-6. Intranasal Pen1-XBIR3 provides short-term protection from tMCAo .......................54 
Figure 3-7. Intranasal Pen1-XBIR3 provides long-term protection from tMCAo .......................55 
Figure 3-8. Intranasal Pen1-XBIR3 reduces ischemic infarct volume .........................................56  
Figure 3-9. Cerebral blood vessels express p75NTR and caspase-9 ............................................58 
Figure 3-10. Caspase-9 regulates BBB integrity and MMP expression during stroke .................59 
Figure 3-11.  Caspase-8 is activated in neonate hypoxia-ischemia ..............................................61 
 
Chapter 4. 
Figure 4-1. Temporal activation of caspase-6 during stroke ........................................................67  
 vi 
Figure 4-2. Cleaved caspase-6 is neuron specific .........................................................................68 
Figure 4-3. Cleaved caspase-3 is glia specific ..............................................................................70  
Figure 4-4. Cleaved caspase-6 is temporally enriched in myelinated axons ................................71  
Figure 4-5. Caspase-6 knockout mice retain processes and neurons following tMCAo ..............73 
Figure 4-6. Caspase-6 knockout preserves neuronal processes ....................................................74   
Figure 4-7. Active caspase-6 observed in human ischemia. .........................................................76  
Figure 4-8. Pen1-XBIR3 reduces caspase-6 activation in tMCAo ...............................................77 
Figure 4-9. Pen1-XBIR3 reduces axon degeneration in tMCAo ..................................................78 
 
Chapter 5. 
Figure 5-1. Proneurotrophins trigger caspase-6 activation ...........................................................85 
Figure 5-2. Penetratin1-Caspase-6 Dominant Negative (C6DN) .................................................86 
Figure 5-3. Pen1-C6DN prevents proneurotrophin-induced death ...............................................87 
Figure 5-4. Neuroprotection with Pen1-C6DN in stroke ..............................................................89 





LIST OF TABLES  
 
Chapter 1. 
Table 1-1. Caspases implicated in stroke pathogenesis ................................................................21  
 
Chapter 2. 
Table 2-1. Rat Neurofunctional Exam ..........................................................................................32  
Table 2-2. Mouse Neurofunctional Exam .....................................................................................33  
 
 
LIST OF ABBREVIATIONS AND ACRONYMS 
AD   Alzheimer’s disease 
BIR   Baculoviral IAP Repeat  
BBB    Blood Brain Barrier 
bVADfmk   Biotin-Valine-Alanine-Aspartate(OMe)-Fluoromethylketone (bVADfmk 
C6-/-   Caspase-6 null 
C6DN    Caspase-6 Dominant Negative 
CARD  Caspase Activation and Recruitment Domains 
CED   Convection-enhanced Delivery 
Cl-C3   Cleaved Caspase-3 
Cl-C6   Cleaved Caspase-6  
CNS   Central Nervous System 
Contra   Contralateral  
DAB    Diaminobenzidine 
DISC   Death-Inducing Signaling Complex  
 viii 
DED   Death Effector Domain 
DEVD   Aspartate-Glutamate-Valine-Aspartate 
Diablo   Direct IAP Binding Protein With Low pI  
ECM   Extracellular Matrix 
FADD   Fas-Associated Protein With Death Domain 
FG    Fluorogold  
GFAP    Glial Fibrillary Acidic Protein  
H&E   Hematoxylin and Eosin 
HtrA2   High-Temperature-Regulated A2  
hpr   Hour Post Reperfusion 
HNE   4-hydroxynonenal  
IL-1β    Interleukin-1 Beta 
IAP   Inhibitor of Apoptosis Protein.  
Ipsi   Ipsilateral 
LACI    Lacunar Infarct 
MCA   Middle Cerebral Artery 
MAP-2   Microtubule-Associated Protein 2  
MMP   Matrix Metalloproteinase 
mRNA   Messenger Ribonucleic Acid 
NeuN   Neuronal Nuclear Antigen 
NF-L   Neurofilament Light Chain 
NGF   Nerve Growth Factor 
ONC   Optic Nerve Crush 
 ix 
OMM    Outer Mitochondrial Membrane   
PACI   Partial Anterior Circulation Infarct   
Pen1   Penetratin1 
PA   Plasminogen Activator 
POCI   Posterior Circulation Infarct   
RGC    Retinal Ganglion Cell  
RNAi   Ribonucleic Acid Interference 
siRNA   Small/Short Interfering Ribonucleic Acid  
miRNA  microRibonucleic Acid  
SDS-PAGE  Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
siCASP2   Caspase-2 Small/Short Interfering Ribonucleic Acid  
SMAC   Second Mitochondria-derived Activator Of Caspases 
SMA   Smooth Muscle Actin  
TJ   Tight Junction   
TIMP-1  Tissue Inhibitor Of Metalloproteinases 1 
TIA   Transient Ischemic Attack 
tMCAo  Transient Middle Cerebral Artery Occlusion 
TNF-R1  Tumor Necrosis Factor Receptor 1 
TACI   Total Anterior Circulation Infarct    
TTC    2,3,5-Triphenyltetrazolium chloride  
Tuj1   βIII-tubulin  
VEID   Valine–Glutamate–Isoleucine–Aspartate 
XIAP   X-linked inhibitor of apoptosis protein 
 x 
XBIR3   X-linked Inhibitor of Apoptosis Protein Baculoviral IAP Repeat Domain 3  
zVAD    benzyloxycarbonyl-Valine-Alanine-Aspartate
 xi 
ACKNOWLEDGEMENTS 
 While my name is the only one on the front of this dissertation, it would be specious to 
believe that this project was performed on my own.   
 First, I would like to thank my doctoral advisor, Carol Troy, for accepting me as your 
student and trusting me with such a wonderful project. I have learned a great deal under your 
tutelage, and I am extremely proud and grateful for what we have been able to accomplish 
together. Thank you. 
 Thank you to my undergraduate advisor at Bard College, Michael Tibbetts. You 
established my scientific foundation. I find myself constantly referring to your sage advice and 
emulating your ethos as a scientist, a mentor, a writer, and an adult, so thank you.  
 Special thanks to my former research mentors at Tufts University. To Marina Chuenkova 
and Mercio PereiraPerrin, thank you for nurturing my confidence and scientific acumen. To 
Henry Wortis and Diana Pierce, thank you for all of your support over the years. Also Di, thanks 
for picking up all of those tabs.  
 I owe an enormous amount of gratitude to my scientific collaborators for aiding the 
execution of this multifaceted project.  
 To Esther Serrano-Saiz, thank you for training me when I first joined Dr. Troy’s lab and 
for your friendship over the years.  
 To E. Sander Connolly and the medical fellows in your neurosurgical unit, Brad 
Zacharia, Andrew Ducruet, and Marc Otten, you have my sincerest gratitude. I must add a 
special thanks to my “strokers”: Greg Cohen, Sergey Sosunov, and Richard Hwang. This project 
completely relied on your deft hands.  
 xii 
 To Guy Salvesen and Scott Snipas at the Sanford-Burnham Institute, thank you for your 
guidance and expertise with caspase inhibitors. To Zubair Ahmed, thank you for testing Pen1-
C6DN in your ocular degeneration model.  
 Many thanks to my thesis committee—Lloyd Greene, Ronald Liem, and Gilbert Di 
Paolo—for your guidance and helpful suggestions towards the completion of this project. Thank 
you to Wilma Friedman and Marc Tessier-Lavigne for participating with my defense committee.  
 To Lloyd Greene, Michael Shelanski, and your lab members, thank you for your 
comments at lab meeting, general scientific advice, and, most importantly, for your camaraderie.  
 I would also like to acknowledge my mentors from my first rotation: Ottavio Arancio, 
Mikako Sakurai, and Elena Leznik. 
  Tremendous appreciation goes to my student “minions”: Jennifer Velloza, Amar Vora, 
Wen Liu, Danielle Fernandes, Alex Kim, and Erin Glennon. I am not sure how you survived my 
mentorship, but I hope that you are better people for it.  Also, many thanks to the past and 
present members of the Troy lab: Ying Jean, Maria-Elena Pero, Sha-ron Pierre, Elena Ribe, 
Rebecca Goldstein, and Nathalie Celcis.  
 To the Pathology coordinator Zaia Sivo, thank you for supporting me from day 1.   
 Finally, it would have been impossible to complete this project without the support of my 
family, to whom this thesis is dedicated, and my close friends. To my parents and sisters, Jacob 
Backon, Tabitha Guzman, David Valdini, Justin Halsey, Mark Halsey, Joanna Halsey, Trevor 
Halsey, Rose Lee, Daniel Pacheco, Matthew Cummings, Karin Kram, Dylan Citrin, Belem 
Bueno, Bri Anne Ryer, Rob Magliaro, Sharon Steiner, Jonathan Mandelbaum, Tiffany Zee, 
Amitabha “Guppy” Gupta, Julio Pozueta, and Yiorgos Mountoufaris… 




























Chapter 1.  Introduction Adapted from [1, 2] 
 
1.1.  Stroke Neurodegeneration  
1.1.1.  Disease Criteria  
A stroke is the sudden loss of neurological function because of a perturbation in the 
cerebral blood supply. Ischemic stroke accounts for the overwhelming majority (80%) of 
recorded cases and is the primary focus of this dissertation. The remainder are either 
hemorrhagic (15%) or idiopathic (5%) [3].  
Ischemia is caused by the occlusion of a cerebral artery by either thrombosis or an 
embolism.  Unlike the related condition, transient ischemic attack (TIA), the symptoms caused 
by an ischemic stroke last for over 24 hours and always result in permanent tissue damage. These 
symptoms include, but are not limited to: hemiplegia, numbness, aphasia, dysarthria, apraxia, 
memory loss, and balance disruption.  
The location of the stroke, symptom presentation, and 
survival are dictated by which cerebral artery is occluded (Figure 1-
1 & 1-2).  
Global ischemia occurs when blood flow to the brain is 
completely stopped, which is a severe complication of cardiac arrest. 
In this event, blood flow is halted in the 4 major arteries that supply 
the brain: the right and left common carotid arteries and the right 
and left vertebral arteries (Figure 1-1) [4]. Clearly, global ischemia is extraordinarily dangerous 
as the brain can only survive for a matter of minutes without blood and oxygen.  
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The long-term consequences of transient ischemic event are dependent on the duration of 
arterial occlusion or cardiac arrest. With the former, the size of the occlusion also factors into 
whether the blockage will break into smaller pieces (“embolize”) and occlude smaller vessels.  
Occlusions in cerebral arteries that are more proximal to the central nervous system 
(CNS) are far more common and pose various threats to neurological function. In 1991, Bamford 
et al. classified these strokes into 4 clinical groups (Figure 1-2; adapted from [4]), based on a 
population study of first-time stroke cases in the Oxfordshire Community Stroke Project (OCSP) 
[5-7]. These groups along with their prevalence1 in the OCSP (blue) and another large-scale 
population study, the Perth Community Stroke Project (red) [8], are:  
1) Total anterior circulation infarcts, TACI (17%, 27%) (Figure 1-2) 
2) Partial anterior circulation infarcts, PACI (34%, 30%) (Figure 1-2) 
3) Posterior circulation infarcts, POCI (24%, 15%) (Figure 1-2) 
4) Lacunar infarcts, LACI (25%, 28%) (Figure 1-2) 
Anterior circulation infarction is the most prevalent subtype of ischemia. A “total” versus 
“partial” classification is dependent on which anterior artery is occluded and the size of the 
affected region. The middle cerebral artery (MCA) is the largest intracerebral vessel and supplies 
nearly the entire convex surface of lateral frontal, parietal, and temporal lobes, along with the 
insula, claustrum, and extreme capsule [9]. MCA occlusion is the most prominent form of 
ischemia and occurs in nearly 90% of anterior strokes [9].  
Symptoms of an anterior stroke typically involve dysfunction in motor and “thought” 
processes: uncoordinated voluntary motion (ataxia), inability to write (agraphia), inability to 
calculate (acalculia), unconscious motion (ideomotor apraxia), inability to draw and build 
(constructional apraxia), and an impairment in understanding language (receptive aphasia).  
                                                








Lacunar stroke results from an occlusion in a blood vessel that supplies the brain’s deeper 
structures, such as the basal ganglia. Common locations include the lenticulostriate branches of 
the MCA or the penetrating branches of the Circle of Willis/posterior arteries (vertebral or 
basilar). Due to the central networking activities of the basal ganglia and the smaller regions of 
injury, clinical presentation of lacunar infarction is extremely varied and often subtle. Infarcts in 
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the thalamus can alter pain perception (i.e., cause numbness and burning sensations), while 
strokes affecting the pons or internal capsule can yield difficulties with swallowing (dysphagia), 
unilateral paralysis (hemiparesis), and speech dysfunction (dysarthria). 
Posterior infarction induces neurodegeneration in the temporal and occipital lobes. As 
expected, the resulting neurological impairments mainly involve sensory perception, balance, 
and facial muscle control [4], such as visual loss (hemianopsia), acquired dyslexia (alexia), 
disabled eye coordination (optic ataxia), impaired pain perception, weakness in upper and lower 
extremities, vertigo, gait disturbances, and facial weakness [4]. 
While the population frequencies for these ischemic subtypes varied between the 
Oxfordshire and Perth studies, mortality rates amongst the various subtypes remained relatively 
parallel [3, 10-13]. Total anterior circulation infarcts (1-yr mortality: ~60%) are 4 times more 
lethal than partial anterior (1-yr mortality: ~15%) and posterior (1-yr mortality: ~15%) 
circulation infarcts. Anterior infarcts are 6 times as lethal as lacunar infarcts (1-yr mortality: 
10%). 
Following occlusion, several mechanisms contribute to the development of neuronal 
injury, including oxidative damage, ionic (Na2+, K+, Ca2+) homeostasis, and inflammation. This 
extensive list of molecular instigators has been thoroughly reviewed elsewhere [14-17], but a 
relevant overview is provided below. 
Stroke injury is morphologically divided into two territories (the core and penumbra), 
which exhibit two prominent modalities of cell death (necrosis and apoptosis).  
Damage in the core is essentially irreversible. In the core, blood perfusion is lowered 
below the threshold for viability, and neurons become electrically silent because of complete 
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energy depletion. Necrosis is the prominent mode of cell death in this region, although there is 
some evidence for apoptosis in the core [1, 17].  
The penumbra circumscribes the core and continues to receive blood from collateral 
arteries after an ischemic event, albeit at lower than physiological levels. Consequently, 
neurodegeneration in the penumbra is more gradual and dominated by apoptosis, which is an 
ATP-dependent process. Markers of apoptosis are found in the penumbra for days to weeks after 
stroke onset.  
Thus, a lengthy window of opportunity is available for targeting apoptotic cascades as a 
means to treat stroke. With timely reperfusion, either spontaneous or therapeutic, this territory 
may be salvaged.  Restoration of blood flow can also induce ‘reperfusion injury’, which 
exacerbates inflammation, excitotoxicity, and apoptotic cell injury [16]. 
Vascular damage accompanies cell death in the stroke infarct [18]. Disruption of the 
neurovascular unit (i.e., the dynamic interactions between microvessels, neurons, astrocytes, and 
microglia) permits the infiltration of inflammatory cells and cytokines that are normally excluded 
from the central nervous system (CNS) by the blood brain barrier. Additionally, stroke induces 
microvascular permeabilization, which causes the extracellular accumulation of fluid. This 
process is known as “cerebral edema”. Edema is the major cause of mortality within the first 24 
hr that follow a stroke, as swelling of the brain leads to herniation and compression of neural 
centers in the brain stem that govern respiration [19].  
1.2. Stroke Therapies  
Trends in mortality and morbidity reveal that modern medicine has failed in the arena of 
stroke. Although 30-day and long-term survival statistics have moderately improved since the 
1960s [20, 21], these gains are largely due to innovations in emergency care. There is still no 
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solution for the progressive neurological destruction that occurs shortly after a stroke. 
Consequently, stroke remains the 3rd and 10th leading cause of death and chronic disability, 
respectively, in the U.S [22-24]. 
Current therapies for stroke can be divided into 2 categories: 
1) Preventative Measures 
2) Acute Interventions 
1.2.1.  Preventative Measures 
 As caspases do not directly factor into preventative measures for stroke, these treatments 
will be briefly discussed. These measures are divided into two categories based on whether they 
are counteracting a nascent stroke (primary prevention) or a possible recurring stroke (secondary 
prevention).  
 Primary prevention targets risk factors [25] that predispose an individual for having a 
stroke. Clinical strategies have focused heavily on reducing hypertension [26], but managing 
smoking habits [27], diabetes [28], cholesterol levels [29], atrial fibrillation [30], and alcohol 
consumption [31] is advantageous as well.   
 Secondary prevention strategies overlap with primary methods (e.g., reducing 
hypertension), but are additionally geared towards improving blood circulation. In this regard, 
antiplatelet agents and anticoagulants are preferred, although they can slightly increase the risk 
of cerebral hemorrhage [3]. 
1.2.2. Acute Interventions 
Three acute remedies have proven efficacious for stroke and are widely practiced.  
1) Aspirin, a validated primary and secondary preventative drug, also improves short-
term mortality (14-day morbidity and mortality [32, 33]) when taken within the first 48 hr after 
 7 
stroke. The overall benefit is relatively small (4 in 1000), but its low cost and simple 
administration justify its use.  
2) As mentioned in “1.1.1 Disease Criteria”, edema is a major cause of mortality during 
the first 24 hr after a stroke. Hemispheric decompression is utilized to relieve the intracranial 
pressure generated by brain swelling and prevent herniation of the brain stem.  This therapy is 
highly beneficial in the rare cases (1 – 10%) where it is required [34]. One small study reported 
78% versus 29% survival when hemispheric decompression was performed for middle cerebral 
artery infarcts [35]. 
3) Tissue plasminogen activator (tPA) is a potent thrombolytic agent (“clot buster”) that 
is used to restore blood flow in the early stages of stroke. It is the only FDA-approved 
neuroprotective drug for ischemic stroke that reduces consequent disability amongst stroke 
patients; however, it fails to improve mortality [3]. As stated in “Chapter 1.1.1 Disease Criteria”, 
reperfusion injury can occur when blood flow is restored to the infarcted tissue, and the duration 
of occlusion directly affects the magnitude of reperfusion injury; i.e. longer occlusions increase 
the likelihood of reperfusion injury. Unfortunately, the use of tPA is restricted to less than 3% of 
the patient pool [36] because of a short treatment window (<3 hr). When given later, tPA induces 
reperfusion injury and can cause hemorrhage. Medical contraindications, such as hypertension, 
also limit its use.   
1.2.3.  Neuroprotection: An Argument for Caspase Inhibition 
Neuroprotection is one possible answer for stroke, but this idea has encountered 
repudiation in recent years. It is frequently quoted that over 1000 neuroprotective treatments 
have been tested and failed in clinical trials for stroke [37]. These nihilistic sentiments are unjust, 
as these setbacks speak to a variety of issues.  
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First, selecting a meaningful drug target for stroke has proven difficult because of the 
myriad mechanisms that are involved with stroke pathogenesis. A majority of the failed 
interventions targeted molecular pathways that are as beneficial in physiological settings as they 
are deleterious during stroke. Thus, poor outcomes are to be expected. Major examples of these 
“Jekyll-Hyde” molecular targets (and their number of failed clinical trials) include glutamate 
antagonists (16), calcium channel blockers (16), and antioxidants (10) [37]. 
Second, timing is a critical determinant in the overall effectiveness of any 
neuroprotective agent. Given that most stroke patients arrive between 5 – 11 hr after stroke onset 
[38, 39] and that stroke neurodegeneration persists for days and weeks, any possible 
neuroprotective target must present a large window of activity (i.e., window of therapeutic 
opportunity) to be effective. 
Third, animal models of stroke provide wonderful insight into ischemic mechanisms, but 
are they accurate facsimiles? Experimental models rely on reproducibility (i.e., inbred rodent 
lines, identical durations of occlusion, controlled rodent size and diet). In contrast, human stroke 
patients have different genetic susceptibilities and are exposed to varying environmental factors 
(i.e., poor diet, hypertension, tobacco exposure, etc.) that contribute to disease outcome. Thus, 
rigorous preclinical testing in a variety of contexts (e.g., different occlusion times, inbred/outbred 
rodent strains, non-human primates, poor diet, etc.) is required for any therapy, neuroprotective 
or otherwise, to be seriously considered for broad use in stroke.   
Cysteine-ASPartic proteASEs (caspases) are key mediators of apoptosis (programmed 
cell death) and neurodegeneration in stroke. The impact of caspase activity is not restricted to 
neuronal death, as caspases can exacerbate inflammation and alter glial function. Given their 
diverse roles in degenerative processes, it is surprising that inhibition of caspases has never been 
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explored in clinical trials for stroke. Apoptosis persists for days to weeks after stroke onset [40, 
41], so caspase inhibition offers a broad therapeutic window. Additionally, inhibiting caspases 
directly targets cell death, rather than targeting broader mechanisms that lead to cell death. 
Finally, expression- or activity-based strategies, which can be used in isolation or 
combination, have demonstrated efficacy in animal models and various preclinical trials. These 
innovations in caspase inhibition offer new potentials for stroke therapy.  
1.3.  Caspases: Focused Overview  
Emblematic of their importance in stroke, caspases contribute to the inflammatory, 
apoptotic, and vascular processes that dominate stroke neurodegeneration (Table 1). In humans, 
apoptotic markers, including cleaved caspases, can be observed in the peri-infarct region from 1 
to 26 days following a stroke [40, 41]. 
Although there are 13 mammalian caspase family members, this section will focus on the 
caspases that have been implicated in ischemic stroke (Figure 1-3; caspase-1, caspase-2, caspase-
3, caspase-6, caspase-7, caspase-8, caspase-9 and caspase-11). For a comprehensive review of 
caspases and neurodegeneration consult [16]. 
1.3.1.  Caspase Classification 
1) Structure  
2) Mechanism of Activation 
3) Cellular Function 
4) Apoptotic Activation Pathways 
5) Receptor-mediated Intrinsic Pathway Activation  
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 1) Structure. Caspases possess a prodomain (Figure 1-3) that is either short (caspase-3, 
caspase-6, and caspase-7) or long (caspase-1, caspase-2, caspase-8, caspase-9, and caspase-11). 
The size and composition of the prodomain determines whether a caspase requires cleavage for 
activation (see ”Mechanism of Activation”).  
All caspases, except for caspase-2, cleave their substrates at an optimal tetrapeptide motif  
(denoted P4-P3-P2-P1) [42, 43]. Caspase-2 prefers a pentapeptide motif (denoted P5-P4-P3-P2-
P1). P1 is the Asp residue that is molecularly attacked by a caspase’s catalytic Cys. P4-P3-P2 
residues interact with corresponding amino acids within the catalytic groove.  
In vitro substrate analysis has demonstrated that each caspase prefers a specific sequence 
of amino acids for P4-P3-P2 [43, 44]. For example, the optimal substrate for caspase-3 is “DEx” 
(Asp-Glu-x; x symbolizes a promiscuous requirement) [43, 44]. Restrictions also exist for the 
residue that immediately succeeds P1, which forms the scissile bond (P1-P1ʹ′) that is cleaved by 
the catalytic Cys. P1ʹ′ is typically a small, uncharged residue (Gly, Ser, Ala).  
It is important to note that in vitro-validated motifs do not always translate to substrate 
specificity in vivo, as tertiary protein structure (i.e., loops or folds) influences the proteolysis of 
natural substrates. 
 2) Mechanism of activation. Caspases are also substrates for caspases. They possess 
target Asp residues in two regions: 1) between the N-terminal prodomain and the large subunit; 
2) between the large subunit and small subunit. Cleavage is required for the activation of some, 
but not all, caspases. 
 Activation occurs upon dimerization because structural changes in the longer intersubunit 
linker allow for the exposure of the catalytic active site. Long prodomains also contain CARD 
(Caspase Activation and Recruitment Domains) or DED (Death Effector Domain) sequences 
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(Figure 1-3). These subdomains interact with complementary regions within an adaptor platform 
molecule (discussed below) to mobilize caspase dimerization/activation. Following proximity-
induced dimerization, initiator caspases can autocleave at P1 Asp residues, but cleavage alone 
does not result in activation [43]. Moreover, cleavage of caspases with long prodomains can 
stabilize their activity (e.g., caspase-8) or increase their ability to be inhibited (e.g., caspase-9) 
[45, 46]. 
In contrast, short prodomain caspases exist as inactive zymogen dimers (Figure 1-4). 
Proteolytic cleavage initially occurs within the intersubunit linker between the large and small 
subunits and is an absolute requirement for activation of caspases with short prodomains. 
For all caspases, a secondary cleavage between the N-terminal prodomain and large 
subunit releases the former; this is typically an autocatalytic event. 
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 3) Cellular Function. Caspases are further generalized into 3 functional groups: 
inflammatory, apoptotic initiator, or apoptotic effector.  
Caspase-1 contributes to stroke inflammation by processing the proinflammatory 
cytokine interleukin-1β (IL-1β) into its active form [47]. During ischemic stroke in rodents, IL-
1β levels rapidly increase in the CNS. Transgenic expression of a caspase-1 dominant negative 
mutant prevents IL-1β maturation and reduces ischemic brain injury [48].  
Recently, genetic knockout of murine caspase-11 was shown to be protective against 
lipopolysaccharide exposure [49], suggesting a role in the innate immune response. In a separate 
study, caspase-11 knockout mice were protected from stroke [50]. Caspase-11 is the probable 
ortholog of human caspase-4 and caspase-5 (59% and 54% homology, respectively); however, 
the latter enzymes have not been directly studied in stroke pathogenesis.  
Coined “Death by a Thousand Cuts” [51], caspase-mediated apoptosis involves the 
selective cleavage of a tremendous number of substrates to promote cellular demolition [52]. 
Apoptotic caspases are classified as either “initiator” or “effector”, which is based on their 
hierarchal nature of activation. Initiators cleave a limited a number of substrates, including 
effector caspases. In turn, effector caspases are charged with propagating cell death by targeting 
a wider variety of protein substrates (e.g., cytoskeleton, kinases, organelles, etc.).  
Notice that caspase structure (short vs. long prodomain) correlates with apoptotic 
function (effector vs. initiator). Caspase-2 is the one exception. It possesses a long prodomain 
but can act as an initiator or effector, depending on the death signal. To add to its uniqueness, 
caspase-2 is also found in the cell as a zymogen dimer [53].   
 4) Activation Pathways. Apoptotic caspases are organized into two canonical signaling 
cascades. The “extrinsic” pathway is dependent on the formation of the death-inducing signaling 
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complex (DISC). Upon ligand binding, a death receptor recruits an adaptor protein, such as the 
Fas-Associated protein with Death Domain (FADD), to the cell membrane. This adaptor protein 
sequesters two caspase-8 monomers into close proximity to induce structural changes that free 
the catalytic site. This trimeric complex (death receptor, adaptor protein, and caspase-8) defines 
the DISC and proceeds to cleave effector caspases. Autocleavage of caspase-8 occurs, which 
enhances its activity. 
The intrinsic pathway is triggered by a variety of cellular stressors (e.g., genotoxicity, 
reactive oxygen species, endoplasmic reticulum stress). The first critical event is the 
permeabilization of the outer mitochondrial membrane (OMM) [54]. Bax and Bak are Bcl-2 
family members that trigger OMM permeabilization. In healthy cells, Bak resides in the OMM, 
while Bax is cytosolic. Death signals cause Bax to translocate to the OMM and induce 
conformational changes in Bax and Bak that lead to their homo-oligomerization. Although the 
precise crystal structure of these oligomerized pores is unknown, it is hypothesized that Bax and 
Bak form pores in the outer membrane that release cytochrome c, the principal killing factor in 
intrinsic apoptosis, into the cytosol [54]. In an ATP-dependent fashion, cytochrome c forms an 
activation platform with APAF-1 that recruits caspase-9 monomers, which subsequently 
dimerize and activate. This caspase 9-based complex, termed the apoptosome, cleaves and 
activates effector caspases. Although caspase-9 does undergo autocleavage, this action does not 
appreciably increase caspase-9 activity. 
Endogenous inhibitors can modulate the intrinsic mitochondrial pathway. Inhibitor of 
Apoptosis Proteins (IAPs), particularly XIAP, inhibits active caspase-3, -7, and -9 (discussed 
below). In turn, Diablo/SMAC or HtrA2/Omi, which are released from permeabilized 
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mitochondria, are IAP antagonists that block IAP inhibition of caspases. Thus, there are multiple 
levels of natural regulation for the intrinsic pathway. 
 5) Receptor-mediated Intrinsic Pathway Activation. Evidence is now pointing towards a 
possible mechanism of receptor-mediated activation for the intrinsic pathway that involves the 
p75 neurotrophin receptor (p75NTR). Mature neurotrophins (~13 kDa), such as nerve growth 
factor  (NGF) and brain-derived neutrophic factor bind to Trk tyrosine kinase receptors to neuron 
survival, proliferation, memory and learning, and axon guidance [55-58]. In contrast, their 
precursor forms—proneurotrophins (e.g., proNGF and proBDNF; 30 – 34 kDa)—are high-
affinity ligands for P75NTR and can signal cell death or cell survival. 
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  P75NTR signals via receptor homodimers as well as heterodimer complexes comprised 
of various co-receptors. The outcome of p75NTR signaling depends upon the receptor complex 
[57, 58]: p75 homodimer (survival), p75NTR-NogoR (axon repulsion), p75NTR-Lingo-1 (axon 
repulsion), and p75NTR-sortilin (neuron and oligodendrocyte death) [59, 60]. P75NTR can also 
associate with Trks to modify Trk ligand binding and signaling [61].   
P75NTR-sortilin induces neuronal apoptosis via a proposed activation pathway [62] that 
involves the recruitment of p75NTR-binding proteins (NRAGE [63, 64], NRIF [65, 66], and 
NADE [67, 68], the activation of c-Jun N-terminal kinases (JNK), the induction of p53/p63, and 
eventual Bax-mediated mitochondrial permeabilization.   
Neurotrophin Receptor–interacting mAGE homolog (NRAGE) promotes cell death by 
preventing p75NTR from associating with Trk receptors [63] and activating the JNK pathway 
[64]. Neurotrophin Receptor Interacting Factor (NRIF) is a zinc finger protein that is 
ubiquitinated after p75NTR stimulation and translocates to the nucleus [69] where is it believed 
to function as transcriptional repressor [70]. NRIF is necessary for p75-mediated JNK activation 
and sufficient for inducing cell death via a p53-dependent mechanism in sympathetic neurons 
[66]. P75NTR-Associated cell Death Executor (NADE) expression is upregulated during 
transient ischemia in CA1 hippocampal neurons [71], and one study demonstrated that it binds 
and prevents SMAC/Diablo from inhibiting the anti-apoptotic actions of XIAP [72]. JNK 
activation mediates p75NTR-triggered apoptosis [73], which increases the expression of p53 and 
p63 [74, 75] Subsequently, p53 induces Bax expression [74, 76, 77], which leads to the 
permeabilization of the mitochondrial outer membrane and caspase-9 activation. 
1.3.2.  Translational Strategies for Caspase Inhibition  
There are three major strategies for inhibiting caspases in stroke.  
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1) Death receptor blockade 
2) Genetic Manipulation 
3) Catalytic Inhibitors 
 1) Death Receptor Blockade. Inhibiting death receptors can disrupt the execution of the 
extrinsic pathway. When administered 30 minutes after stroke, antibodies against tumor necrosis 
factor-receptor-1 (TNF-R1) and CD95, members of the TNF receptor superfamily, can reduce 
neural injury [78].  
 2) Genetic Manipulation. Ischemic stroke induces caspase expression (mRNA and/or 
protein) within the first 24 hr for all of the caspases mentioned above [16] (Table 1). 
Furthermore, genetic knockout of caspase-1, caspase-3, caspase-6, or caspase-11 is 
neuroprotective against stroke [1, 16].  
Obstacles for an RNAi-based gene therapy for caspases include sufficient distribution of 
the therapeutic siRNA/miRNA to susceptible CNS regions and efficient delivery into neuronal 
cells. A proof-of-concept study recently overcame these issues with a nonviral-based RNAi 
system in a rodent ischemia model [79]. Immediately before the induction of stroke, carbon 
nanotubes loaded with caspase-3 siRNA were stereotactically delivered into motor cortices. 
Neurons in the treated regions were protected against stroke, and neurological function was 
preserved.  
Viral delivery is another option [80], but this strategy is hampered by the fact that viral 
vectors are immunogenic [81] and have limited capacity for DNA/RNA payloads [80]. 
Additionally, they can be difficult to mass-produce and have limited stability after production 
[80].  
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Certain drugs can also modify caspase expression. Minocycline inhibits caspase-1 
expression during stroke [82] and has the additional benefit of inducing the expression of anti-
apoptotic Bcl-2 [83]. However, drug-based knockdown often lacks complete molecular and 
tissue specificity, with compounds like minocycline affecting a variety of gene targets and 
organs. For example, minocycline has anti-inflammatory properties; it can alter T-cell and 
microglia function [84] and is beneficial in inflammatory diseases like multiple sclerosis [85] 
and rheumatoid arthritis [86]. However, chronic minocycline therapy can trigger immune 
disorders like lupus and autoimmune hepatitis [87, 88].  
Gene therapy is an effective prophylactic strategy, but the true litmus test for any stroke 
treatment is potency after ischemia has begun. In this regard, gene therapy might have limited 
utility even in the best scenarios. Caspases are expressed at modest levels in the CNS, which 
means there is an available pool of death molecules at stroke onset. Therefore, caspase activation 
could be appreciable before a gene therapy could significantly curtail expression.  
For further review on the potential of gene therapies for stroke consult: [80] 
 3) Catalytic Inhibitors. For nearly 20 years, short peptide inhibitors have been the 
principle tools for studying and manipulating caspase activity. Based on the optimal substrate 
motif (P4-P3-P2-P1) of an individual caspase, these synthetic inhibitors can be modified by 
adding chemical moieties to determine their reversibility and membrane permeability. The pan-
caspase inhibitor zVAD (benzyloxycarbonyl-Val-Ala-Asp) and putative caspase-3 inhibitor 
DEVD confer neuroprotection in rodent models of stroke [89]. Although they have never been 
tested in clinical trials for stroke, trials are underway for the use of these peptide-based inhibitors 
for liver injury and psoriasis [42]. 
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However, multiple studies have demonstrated that short peptide inhibitors are highly 
promiscuous [90, 91]. Given that certain caspases have non-death roles in synaptic plasticity and 
microglial activation [92, 93], this lack of specificity could potentially reduce the overall 
usefulness of peptide-based inhibitors in stroke. 
 Natural protein biologics that inhibit caspases offer higher target specificity and an 
alternative to short peptide inhibitors. Given their larger size, most biologics require assistance to 
cross the plasma membrane. Trojan peptides (e.g., Tat or Penetratin1) can be utilized towards 
this goal.  
As discussed in Chapters 3 & 4, we recently applied this delivery strategy to a biologic 
derived from a metazoan caspase inhibitor [1]. Mammals express a family of cell death 
inhibiting proteins known as IAPs or Inhibitors of Apoptosis Proteins. IAPs contain baculoviral 
IAP repeat (BIR) domains, which perform specific functions. One member of this family, X-
linked IAP (XIAP), is a potent, specific inhibitor of active caspases-9, -3, -7. IAPs are comprised 
of baculoviral IAP repeat (BIR) domains. For XIAP, caspase inhibition specificity is dependent 
on the BIR domains. The BIR3 domain is a specific inhibitor of active caspase-9, while the BIR2 
domain inhibits active caspases-3 and -7 [94]. 
XBIR3 can only inhibit caspase-9 after autocleavage [94]. Rather than target the catalytic 
site of caspase-9, XBIR3 uses a less conventional method of inhibition. Biochemical and crystal 
structure analysis demonstrates that XBIR3 inhibits caspase-9 by severing the dimer interface, 
which functionally separates an active caspase homodimer into inactive monomers [94-96]. 
XBIR3 accomplishes this feat by binding two IAP-binding motifs (IBM) located in the active 
caspase-9 dimer. One IBM is generated at the amino-terminus of the small subunit, following its 
separation from the large subunit. The other IBM is located at the dimer interface. 
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In Chapters 3 & 4, we show that a Trojan peptide—Penetratin1  (Pen1) —can be linked 
to XBIR3 via a disulfide bond to deliver this caspase inhibitor into the intracellular compartment. 
Pen1 is the third homeodomain (16 aa) from the Drosophila transcription factor Antennapedia, 
and due to its charge and small size (see below), it can cross biological membranes [97].  Upon 
cellular entry, this transient linkage is reduced by the cytoplasmic pH, and the cargo is allowed to 
act on its intended target. When given intranasally, as a prophylactic or therapeutic, Pen1-XBIR3 
prevented the activation of the intrinsic pathway (i.e., subsequent caspase-6 activation) and 
provided substantial neuroprotection against stroke. Additionally, it was revealed that caspase-9 
inhibition reduces cerebral edema. As previously stated, edema is a major cause of mortality 
within the first 24 hr after stroke.  
 Trojan peptides could usher in a new era in resolving caspase mechanisms and treating 
cell death. Examples of Trojan peptides, which are typically short (16-35 aa) and partially 
hydrophobic, include Pen1, HIV-1 TAT protein, VE-cadherin-derived cell-penetrating peptide, 
and transportan [98]. Most Trojan peptides are polybasic and retain a net positive charge at 
physiological pH.  All Trojan peptides are lipophilic, and many are also amphipathic. Uptake 
mechanisms include direct penetration and endocytosis. 
Along with intracellular targeting, these transport peptides have other distinct advantages. 
For example with Penetratin1, the upper limit for the molecular weight of peptide cargo is ~100 
kDa. Pen1 can also be adapted to deliver siRNA. Other peptide inhibitors require evaluation with 
this Trojan peptide delivery. Alternatively, endogenous substrates or catalytic dominant 
negatives, as shown in Chapter 4, can be attached to Trojan peptides and used as competitive 
inhibitors.  
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One disadvantage of using Pen1 is a lack of cellular specificity; i.e., it will deliver to all 
cell types. For discrete transport to neurons, rabies virus glycoprotein can be used to deliver 
peptides and siRNA [99, 100]. Similarly conceived Trojan peptides from various tissue-tropic, 
viral-entry proteins could offer innovative methods for organ-specific drug delivery. Another 
disadvantage is that the net positive charge of Trojan peptides can generate solubility issues after 
linkage to cargo.  
1.3.3.  CNS Delivery Methods 
The blood brain barrier (BBB) evolved to protect the CNS from molecular insults, but it 
also restricts the passage of many neuroprotective agents administered into the bloodstream. 
Routes for bypassing the BBB do exist. Intranasal delivery is proving efficacious for 
accessing the CNS and treating neurodegenerative disease [101]. For example, cognition is 
significantly improved after intranasal administration of insulin in early clinical trials for 
Alzheimer’s disease and mild cognitive impairment [102]. This method provides 100-fold higher 
CNS concentrations relative to intravenous administration [103]. Alternatively, more invasive 
methods that utilize direct injection into the brain (e.g., intracerebral and intraventricular) are 
clinically viable, although less favorable from a patient’s viewpoint.  
1.3.4.  Axon Degeneration, Caspases, and Stroke 
Axon degeneration precedes neuronal death in many neurodegenerative diseases, and is 
an oft neglected target for therapies [104]. Axon degeneration occurs in humans during stroke 
with diffusion tensor imaging revealing extensive loss of axonal tracts in the stroke penumbra 
[105, 106].  
However, following a brain insult, preservation of neuronal connections is vital in 
retaining neuronal functions. In the stroke penumbra in gerbils, Ito et al. found that corticofugal 
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axon and synaptosome density decreased at approximately 12-24 hr post-reperfusion and 
continued until 4 days post-occlusion [107, 108]. In rats, stroke reduces axon density in the 
forebrain, midbrain, and brainstem [109]. Large amounts of axonal swelling occur immediately 
following an ischemic event as well as after traumatic brain injury. While the relationship  
Table 1-1. Caspases implicated in stroke pathogenesis. 
Caspase Paradigm (Species) Measure Reference 
1 tMCAo (mouse) Genetic Knockout  (infarct 
size, cerebral blood flow, 
brain edema) 
[110] 
1 pMCAo (mouse) Ac-YVAD-AFC (catalytic 
activity) 
[111] 
1 pMCAo (rat) mRNA levels [2] 
      
2 Global Ischemia (rat) caspase cleavage (WB, IHC) [112] 
    
3 tMCAo (mouse) Genetic Knockout  
 (Infarct Volume, neuron 
density, TUNEL) 
[113] 
3 pMCAo (rat) caspase cleavage (WB) [114] 
3  pMCAo (mouse) Ac-DEVD-AFC (catalytic 
activity), caspase cleavage 
(WB, IHC) 
[111] 
3  pMCAo (rat) mRNA levels [2] 
    
6 pMCAo (rat) mRNA levels [2] 
6 tMCAo (mouse, rat) Caspase cleavage (IHC), 
knockout mice (Infarct 
volume, motor behavior) 
[1] 
    
7 pMCAo (rat) mRNA levels [2] 
    
8 pMCAo (rat) mRNA levels [2] 
   pMCAo (mouse) Ac-IETD-AFC (catalytic 
activity), caspase cleavage 
(WB, IHC) 
[111] 
   pMCAo (rat) Caspase cleavage (WB) [114] 
    
9 tMCAo (rat, mouse) Caspase cleavage (IHC), 
biochemical isolation of 
[115], [1] 
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active caspase 9 
  tMCAo (canine)  Release of caspase 9 from 
mitochondria 
[116] 
 Human Stroke tissue IHC [117] 
    
11 pMCAo (rat) mRNA levels [2] 
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between caspase activation and axonal swelling has not been evaluated in ischemia, cytochrome 
c release and caspase activation are present early in axons after traumatic brain injury [119]. 
Wallerian degeneration is a term applied to the ‘dying back’ phenomenon observed by 
axons that have been transected [120]. Transected axons initially degenerate at the distal tip and 
disintegrate in a retrograde manner. In mutant WldS (slow Wallerian degeneration) mice, axons 
display significant retardation of Wallerian degeneration following axon transection. WldS mice 
are often utilized to evaluate the contribution of Wallerian degeneration in neurodegenerative 
disease models.  For example, WldS mice are protected against ischemia, which indicates that 
Wallerian degeneration contributes to ischemic damage [121], although the molecular 
mechanisms have not been resolved. 
It has been proposed that Ca2+-activated proteases (calpains) mediate Wallerian 
degeneration of axons, while it is strongly asserted by others that caspases are not involved [122, 
123]. Bcl-2 overexpression as well as the deletion of proapototic Bax and Bak fail to rescue 
retinal and optic nerves from Wallerian degeneration [124, 125]. However, caspases do mediate 
axon degeneration in the setting of neurotrophin withdrawal [126, 127].  Activated forms of 
caspase-3 and caspase-6 are found in the axons of dorsal root ganglion neurons following local 
neurotrophin withdrawal [126, 127]. Interestingly, caspases direct dendrite remodeling, a process 
similar to Wallerian degeneration, in a non-apoptotic setting in Drosophila [128, 129]. Activated 
caspase-3 is also found in projections of neurons undergoing developmental apoptosis [130].  
1.4.  Molecular Mechanisms of Cerebral Edema 
A small, but significant, portion of this dissertation focuses on the role of caspases in 
cerebral edema. We discovered a novel relationship between this vascular pathogenic process 
and caspases; thus, a discussion on the mechanisms of cerebral edema is warranted. 
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1.4.1.  Types of Cerebral Edema. 
Cerebral edema is defined as a pathological increase in the total water content of the 
brain, which subsequently increases brain volume. If left unchecked, tissue swelling will increase 
intracranial pressure, compress capillaries (causing local ischemia), and herniate the brain, which 
is fatal. There are three classes of cerebral edema: cytoxic, vasogenic, and interstitial.  
 Cytoxic edema is caused by a disruption in cellular homeostasis due to impaired Na+/K+-
ATPase pumps. As a result the Na+/K+ gradient is abolished, and sodium ions along with water 
are retained within the intracellular compartment. This event disrupts the electrochemical 
gradient that is required for cellular function, but cytotoxic edema is reversible in some 
scenarios, such as with transient ischemic attacks [131].  
 Vasogenic edema results from an increase in vascular permeability in the BBB. Thus, 
Na+, water, and serum proteins in the main vascular circulation leak into the brain parenchyma 
and cause swelling. While conversion from edema into hemorrhage is possible [132, 133], this 
topic will not be discussed in this dissertation. 
 Diminished absorption of cerebral spinal fluid is the underlying cause of interstitial 
edema. Either an obstruction within the ventricles or increased production of cerebral spinal 
fluid can spawn this condition. Interstitial edema is not typically a complication of ischemic 
stroke, although it is observed with hemorrhage [131], so it will not be discussed further. 
  Cytotoxic edema contributes to pathogenesis in cerebral ischemia during the early stages 
of stroke (hours – days) [134]. The connection between ischemia and cytotoxic edema is simple: 
decreased blood flow means less energy/ATP production in the brain, which impairs Na+/K+-
ATPase pumps and neuronal function.  
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However, it is unlikely that cytotoxic edema in isolation can elevate intracranial pressure 
to the point of brain herniation. Indeed, one can argue that brain water content remains the same; 
water merely transitions from the extracellular space to the intracellular compartment.  
 In contrast, brain volume is significantly elevated by vasogenic edema, which occurs on 
the timescale of days to weeks after stroke onset in humans. While the consequences of 
vasogenic edema are obvious (e.g., herniation), the cellular and molecular events that trigger 
pathophysiology are barely understood.  
1.4.2.  The Blood Brain Barrier and the Neurovascular Unit 
The crucial event in vasogenic edema is the breakdown of BBB integrity. The structure 
of the BBB is comprised of the capillary lumen that is completely defined by an endothelial cell 
monolayer. Endothelial cells are ensheathed in a layer of basal lamina on the abluminal side, 
and the apposing membranes of each adjacent cell are connected and sealed by tight junctions 
(TJ). Residing on top of the basal lamina are pericytes, which are in turn covered by another 
layer of basal lamina, which separates the pericytic layer from the parenchyma. Finally, 
astrocyte end-feet and neuronal axon terminals are within close proximity to the vessel 
structure; they provide chemical and enzymatic signals that regulate BBB permeability. Given 
the tremendous metabolic demands of neurons, it is not surprising that neurons and their glial 
support cells influence BBB, which governs nutrient transport from general vascular circulation. 
These six components—endothelial cells, basal lamina, TJs, pericytes, astrocytes, and neurons—
are known as the neurovascular unit. 
1.4.3.  Proteases Govern BBB Integrity During Ischemia 
 During cerebral ischemia, two families of proteases—plasminogen activators (PAs) and 
matrix metalloproteinases (MMPs)—act in concert to open the BBB by breaking down the 
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extracellular matrix. Plasminogen activators are serine proteases that cleave the zymogen 
plasminogen into its active form, plasmin. Plasmin, which is typically associated with 
fibrinolysis, can only cleave a limited number of targets in the vascular ECM, such as laminin 
and fibronectin [135].  
However, plasmins can directly and indirectly activate MMPs [135], which in turn cleave 
a larger volume of substrates (see below). Interestingly, when recombinant tPA is given after its 
recommended window (< 3 hr), it contributes to edema and hemorrhagic transformation, 
arguably through the activation of MMPs [136].  
MMPs are zinc-dependent enzymes that are secreted or membrane bound. Relative to 
plasmin, MMPs proteolyze a broader range of vascular ECM proteins (e.g., laminin, fibronectin, 
gelatins, collagens, elastin, and perlecan [135, 137]). Additionally, MMPs can disrupt the BBB 
by cleaving TJ proteins: claudin-5 and occludin [138, 139].  
Two MMPs have been strongly linked with the development of ischemic edema: MMP-2 
and MMP-9. In ischemia-reperfusion models (rodent and non-human primates), MMP-2 
expression/activity increase in the early stages (within 3 hr of reperfusion) [140-142], which 
corresponds with an initial opening of the BBB and the loss of TJ proteins by 24 hr [138]. A 
second wave of edema occurs between 24 – 48 h that correlates with an increase in MMP-9 
expression/activity and MMP-9-dependent vascular damage [139, 141, 142]. Elevated MMP-9 
expression also correlates with hemorrhagic transformation and intracerebral hemorrhage [143]. 
MMP-3 has been recently implicated in BBB disruption during ischemia [144, 145]. 
However, it is unclear whether TJ and ECM proteins are directly targeted by MMP-3 proteolysis 
or if MMP-3 is an upstream activator of MMP-2 and MMP-9 in this scenario.  
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MMP-9 is mainly expressed by endothelial cells and pericytes, while astrocytes are a 
major source of MMP-2 [139]. Pericytes also express MMP-3.  
Given that many MMPs are constitutively expressed, it is not surprising that a family of 
endogenous inhibitors exists to regulate MMP activity. Tissue inhibitors for metalloproteinases 
(TIMPs) are small proteins (between 21 and 28 kDa) that regulate MMP activity [146].  
Of the 4 variants (TIMP 1-4), expression levels of TIMP-1 and TIMP-3 are elevated 
during ischemia in a timeframe that coincides with MMP induction, which is perceived as a 
natural attempt to temper BBB opening. TIMP-1 has a preference for MMP-9; however, like 
TIMP-3 and other TIMPs, it is a broad spectrum MMP inhibitor [139]. 
MMPs are also known to cleave proneurotrophins in the extracellular milieu, which has 
implications for neurodegeneration [147, 148]. In particular, MMP-7 is sufficient for the 
processing of proneurotrophins into their mature forms in vivo [147-150]. Proneurotrophins are 
increased during kainic acid-induced seizures [69, 147], and this event coincides with a decrease 
in MMP-7 levels and an increase in the expression of its endogenous inhibitor TIMP-1 [147]. 
Thus, MMPs are dynamic regulators of proneurotrophins, which as discussed earlier are pro-
apoptotic in nature. 
1.4.4.  Pericytes Contribute To Ischemic Cerebral Edema 
Pericytes provide contractile support for the brain’s vast network of microvessels, where 
there is a 1:3 pericyte:endothelia ratio[151]. (By contrast in striated muscle, where there are 
fewer microvessels, the pericyte:endothelia ratio is 1:100.)  Along with maintaining capillary 
blood flow and producing endothelial survival factors (e.g., angiopoetin-1) [45], pericytes are 
integral players in BBB integrity because they induce TJ protein expression, during embryonic 
development [152] and in adulthood [153], and are also a major source of MMPs [139].  
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Additionally, pericytes contract early in rodent models of transient middle cerebral artery 
occlusion and remain contracted for at least 6 hours after reperfusion [154]. This event restricts 
blood flow, which exacerbates the ischemic condition. Pericyte contraction in this diseased state 
has been linked to intracellular Ca2+ dysregulation and excess ROS generation [45]. 
1.5.  Significance and Outline 
 The following chapters are an exploration in the relationship between caspase biology 
and the pathogenic mechanisms of cell death and edema in ischemia. Caspases significantly 
contribute to neurodegeneration in stroke; thus, these proteases are ideal therapeutic targets. 
Transient ischemia is a wonderful in vivo model for studying caspase biology (e.g., developing 
activity assays and studying enzyme inhibition) because there is robust caspase activation. 
Chapter 2 outlines the experimental methods that were utilized in the study. Chapter 3 
details how initiator caspases are critical mediators of cell death and edema during stroke. New 
tools for the analysis of caspase activity and innovative caspase inhibitors are discussed. Chapter 
4 advances down the caspase hierarchy and deals with the role of executioner caspases in 
cerebral ischemia. A novel relationship between caspase-6, cerebral ischemia, and axon 
degeneration is expounded, which was followed by the development of a dominant-negative 
inhibitor for caspase-6, as discussed in Chapter 5. Chapter 6 provides the conclusions and future 
directions for the project.  
Overall, this dissertation describes previously unknown functions for caspases in stroke 
pathogenesis and strengthens the argument for caspase-based therapies for stroke 
neurodegeneration.   
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Chapter 2.  Materials and Methods 
 
2.1. Rodent Husbandry and Handling.  
All rodent procedures were approved by the Columbia University Institutional Animal 
Care and Use Committee. 
2.1.1. Mouse Breeding. Caspase-6 null (C6-/-) mice (Jackson Laboratories, Bar Harbor, ME) 
[155, 156] on C57/Bl6 background were bred with wild-type C57/Bl6 mice to generate C6+/- 
heterozygotes. Heterozygotes were then bred to generate C6-/- and wild-type littermates for 
studies.  
2.1.2. Transient Middle Cerebral Occlusion. Male C6-/- and wild-type littermate mice (23-30 
g; aged 2-3 months) as well as adult Wistar male rats (250-300 g; aged 12 weeks, Taconic 
Laboratories, Germantown, NY) were subjected to transient middle cerebral artery occlusion 
(tMCAo) as previously published [157, 158]. Rats and mice were anesthetized using isoflurane 
delivered in a mixture of nitrous oxide (70%) and oxygen (30%) via facemask. TMCAo was 
accomplished with a 25 mm 4-0 nylon suture (5 mm silicone rubber tip) to occlude the MCA. 
Rats received 120 min occlusion, while mice received 45 min or 60 min. To confirm cerebral 
ischemia, transcranial measurements of cerebral blood flow (CBF) were made using laser 
Doppler flowmetry (LDF) over the MCA territory (1.5 mm posterior and 5.5 mm lateral to the 
bregma). A reduction in the LDF reading to at least 40% of baseline was defined as an adequate 
CBF drop-off. The degree of functional deficit at 1 hour post-occlusion was scored using a 
modified 5-point Bederson scale, which measures forelimb flexion, resistance to lateral push, 
and circling behavior. Animals with a Bederson’s score less than 1 (no deficit) were excluded 
from analysis. Rodents were placed in a 37°C post-operation incubator and maintained at 
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normothermia for an hour. Brains were harvested and processed for western blotting or 
immunohistochemistry, as described below. 
2.1.3. Neonate Hypoxia-Ischemia. Caspase activity was measured in the Rice–Vannucci 
model of hypoxia-ischemia brain injury adapted to postnatal day 9 (P9) to P10 neonatal mice 
[159, 160]. P3 C57/BL6/J mice, along with their birth mothers, were purchased from Jackson 
Laboratories. On P7, mice were anesthetized with isoflurane, while the right carotid artery was 
permanently ligated.  After 1.5 hr of recovery, pups were exposed to 15 min of hypoxia (8% O2 
with balanced N2) in a hypoxic chamber. Ambient temperature during hypoxia was maintained 
at 37.0–37.5°C by placing the hypoxic chamber in a neonatal isolette (Airshield).  
 To measure caspase activity in pups, bVAD-fmk was stereotactically injected into the 
predicted area of infarction (0.2 µL/min immediately before permanent ligation of the carotid. 
Pups were sacrificed 1 hr after hypoxia. Infarcted brain tissue was excised and flash frozen with 
liquid nitrogen. A corresponding sample (internal control) was also dissected from the 
contralateral hemisphere.  
2.1.4. Stereotactic Injection. Adult male Wistar rats (250-300 g) were anesthetized using 
isoflurane (2%) delivered via an anesthesia mask for stereotactic instruments (Stoelting, Wood 
Dale, Illinois) and positioned in a stereotactic frame. Convection-enhanced delivery (CED) was 
performed as previously described [161]. The scalp was shaved, and the skin was prepped with 
iodine solution and bupivicaine (0.25 ml of 0.25% solution). A 1.0-1.5 cm incision was made in 
the midline of the scalp to expose the bregma. A 1 mm burrhole was created at the coordinates 1 
mm anterior and 3 mm lateral to the bregma. For the acute stereotactic infusions, a 28-gauge 
cannula was inserted to a depth of 5 mm below the dura into the caudate nucleus [161]. Infusion 
of the therapeutic was then instituted at a rate of 0.5 µl/minute. Following infusion, the cannula 
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was removed at a rate of 1 mm/minute, and the burrhole was sealed with bonewax. The skin 
incision was closed with skin adhesive. Post-procedure, rats were placed in a 37°C post-
operation incubator and maintained at normothermia for an hour.  
To inhibit caspase-9 pathways in vivo, Pen1-XBIR3 (30 µl of 36.8 µM solution) was 
infused immediately prior to induction of ischemia. Animals were housed at room temperature 
until they were euthanized. Brains were processed for immunohistochemistry (see below) or 
protein isolation (brain tissue dissection followed by snap-freezing in liquid nitrogen).  An 
equivalent volume of saline was infused in negative control animals. 
2.1.5.  Intranasal Injection. While under isoflurane anesthesia, animals were placed so that 
they were lying on their backs. For rats, Pen1-XBIR3 (36.8 µM) was delivered by administering 
6 µl drops to alternating nares every two minutes for 20 minutes (60 µl in total) [103]. For mice, 
Pen1-C6DN (31.9 µM) was delivered by administering 2 µl drops to alternating nares every 
minute for 10 min (20 µl in total) [103]. Pen1-XBIR3 intranasal treatment was done either prior 
to stroke or 4 hr after reperfusion. Pen1-C6DN was only given prior to stroke. Saline was used as 
a negative control. For non-stroked controls, animals were given 60 µl of vehicle or Pen1-XBIR3 
and anesthetized for the same period of time as stroked animals (~1.25 hr). Brains were 
harvested for immunohistochemistry or western blotting. 
2.1.6.  Behavioral Examinations. For rat neurofunctional analysis, a 24-point neurological 
functional exam was developed by adapting strategies from previous studies [162-165] into a 
single exam (Table 2-1). Groups were analyzed by ANOVA. For mouse neurofunctional analysis 
(Table 2-2), a 28-point neurological functional exam was performed as previously described 
[166], with group comparisons made with Student’s t-test. Additionally, for the WT vs. C6-/- 
experiments, a single mouse from each genotype was placed in isolation in a fresh cage, and 
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short videos (3 min at each time point) of spontaneous activity were recorded at three time points 
(pre-stroke, 24 hr reperfusion, 7 days reperfusion) to track motor decline. 
Table 2-1. Rat Neurofunctional Exam 
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Table 2-2. Mouse Neurofunctional Exam 






Circling Behavior 0-4 
Front Limb Symmetry 0-4 
Compulsory Circling 0-4 
Vibrissae Response 0-4 
Total Score 0 = Normal Motor Function 
28 = Severe Motor & Sensory Deficits 
 
2.2  Peptide Inhibitors for Caspases 
2.2.1.  Peptides  
Penetratin1.  The Trojan peptide Penetratin1 (Pen1) was custom made by (NeoMPS, San Diego, 
CA). Amino Acid Sequence: RQIKIWFQNRRMKWKK (16 AA) 
X-linked Inhibitor of Apoptosis Protein BIR3 Domain (XBIR3). The BIR3 domain from X-
linked Inhibitor of Apoptosis Protein (XBIR3) was purified by our collaborators Scott Snipas 
and Guy Salvesen (Sanford-Burnham Institute) as previously described [167]. Stock 
concentration: 36.8 µM. Amino Acid Sequence: 
NTLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYALGEGDKVKCFHCGGGLTDWR
PSEDPWEQHARWYPGCRYLLEQRGQEYINNIHLTHS (94 AA). 
Caspase-6 Dominant Negative (C6DN). Mutant Caspase-6 (Cys163Ala) dominant negative 
(C6DN) was cloned with NdeI/XhoI sites but the NdeI is not unique. C6DN was cloned by 
partial digestion into pET23b. C6DN was purified in our labs as previously described [168]. 
Stock concentration: 63.2 µM.  


























HHHHHH (302 AA) 
2.2.2.  Penetratin1 Linkage. Penetratin1 was mixed at an equimolar ratio with purified peptides 
(i.e., XBIR3 or C6DN) and incubated overnight at 37°C to generate disulfide-linked Pen1-
peptide. Linkage was assessed by 20% SDS-PAGE and western blotting with anti-His antibody.  
Alternatively, SDS-PAGE gels were stained with Coomassie or SYPRO Ruby (Sigma-
Aldrich). First, gels were soaked with isopropanol fixing solution (10% acetic acid, 25% 
isopropanol; v/v in ddH2O) for 30 min. They were then incubated with Coomassie Brilliant Blue 
(0.006% in 10% acetic acid) for 3 hr or overnight, which was followed by destaining (10% acetic 
acid) for 1-2 hr.  
For gels stained with SYPRO Ruby, gels were first soaked with methanol fixing solution 
(7% acetic acid, 50% isopropanol; v/v in ddH2O) for 30 min. They were then incubated 
overnight with 1x SYPRO Ruby (Bio-Rad #170-3126), which was followed by destaining (10% 
methanol, 7% acetic acid) for 1-2 hr. 
SYPRO Ruby or Coomassie stained gels were imaged on an UV transilluminator and 
white light box, respectively.  
2.2.3. Rhodamine Labeling of Peptides. C6DN (100 µL of 31.9 µM solution) or XBIR3 (100 
µL of 36.8 µM solution) were buffer exchanged with ZebaTM desalt spin columns (Thermo 
Fisher Scientific, Waltham, MA) into 1x phosphate buffered saline (PBS). Buffer exchange is 
needed to remove primary amines (e.g., Tris or glycine), which can react with the NHS-ester 
moiety and compete with the intended reaction. Following buffer exchange, protein 
concentrations were determined using the Bradford colorimetric protein assay (Bio-Rad, 
Hercules, CA), according to the manufacturer’s protocol. NHS-Rhodamine was added to the 
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peptide at a 10:1 molar ratio. These reactions were incubated on ice for 2 hr. Non-reacted NHS-
Rhodamine was removed with fresh ZebaTM desalt spin columns, and protein concentrations 
were reanalyzed. Rhodamine-labeled peptides were stored at 4°C and protected from light until 
the day of Penetratin1 linkage. 
2.3.  Biochemical 
2.3.1. In Vivo Caspase Activity Assay. Biotin-Val-Ala-Asp(OMe)-Fluoromethylketone 
(bVADfmk, MP Biomedicals, Santa Ana, CA; stock dissolved in DMSO) was used as an in vivo 
molecular trap for active caspases. BVADfmk (200 nmoles) was diluted in 30 µl sterile saline 
and infused by CED either prior to stroke or 3 hr after reperfusion in rats. After treatment with 
bVADfmk and tMCAo, brain tissue was harvested and flash frozen in liquid nitrogen. Tissue 
was lysed by pestle disruption in cold CHAPS buffer or bVAD buffer (Appendix I. Cell Lysis 
Buffers) containing protease inhibitors (Roche, Indianapolis, IN). Protein concentrations were 
determined using the Bradford colorimetric protein assay (Bio-Rad), according to the 
manufacturer’s protocol. 
For bVAD fmk-caspase complex precipitation, protein lysates (100 – 120 µg) were pre-
cleared by rocking with Sepharose beads (GE Healthcare, Pittsburgh, PA) for 1.0 hr at 4°C. Pre-
cleared lysate was centrifuged, and the supernatant was transferred to 30 µl of Streptavidin-
agarose beads (Sigma-Aldrich, St. Louis, MO) and rocked gently overnight at 4°C. Beads were 
washed and centrifuged (300 µl washes, 5000 rpm for 5 minutes) with lysis buffer. This step was 
repeated 15 times to remove non-specific binders. After the final wash and pelleting, caspase-
bVADfmk complexes were extracted from streptavidin beads by boiling in 1x SDS sample 
buffer (non-reducing conditions, Appendix I Cell Lysis Buffers). Beads were pelleted at 14,000 
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rpm for 10 minutes, and the supernatant was transferred to a fresh tube and resolved by SDS-
PAGE. Saline was used in vehicle animals to act as a precipitation control for bVADfmk. 
2.3.2. Axon Fractionation. Following dissection, brain tissue was dissociated with a Dounce 
homogenizer in 500 µL of Isolation Buffer (listed below). Homogenate was transferred to 1.5 
mL microfuge tubes and centrifuged at 10,000 x g for 15 min. The myelin float layer (200 µL) 
was transferred to a fresh microfuge tube, and Dounce homogenization/centrifugation was 
repeated twice. The soluble fraction was separated into fresh microfuge tubes and flash frozen; 
the pellet, which contains unmyelinated axons and nuclei, was discarded.  
 The myelin float layer was further Dounce homogenized with Demyelination Buffer 
(listed below). Samples were subsequently incubated while rocking for 1 hr at 4 °C. Axoplasm 
proteins were pelleted by centrifuging at 10,000 x g for 15 min, and supernatant was discarded. 
The resulting pellet was washed with Wash Buffer (listed below) and centrifuged at 10,000 x g 
for 15 min. This step was repeated 2 additional times. After the final centrifugation step, the 
pellet was resuspended in 25 – 50 µL of RIPA lysis buffer. Samples were resolved by SDS-
PAGE and analyzed by western blotting.  
Isolation Buffer (pH 6.6): 100 mM NaCl, 10 mM phosphate buffer (0.0964% NaH2PO4-
H2O & 0.0808% Na2HPO4-7H2O), 5 mM EDTA, 0.85 M sucrose. Demyelination buffer (pH 
6.6): 100 mM NaCl, 10 mM phosphate buffer, 5 mM EDTA, 1% Triton-X. Wash Buffer (pH 
6.6): 100 mM NaCl, 10 mM phosphate buffer, 5 mM EDTA. 
2.3.3.  Quantification of Edema by Evans Blue Dye Extravasation. Vascular permeability 
was quantitatively evaluated by fluorescent detection of extravasated Evans blue dye (Sigma 
Chemical)[169].  After MCA occlusion in mice, 2% Evans blue dye (w/v in saline) was injected 
intravenously (4 mL/kg) as a tracer of blood brain barrier permeability. Evans blue dye was 
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injected and allowed to circulate for 30 minutes, prior to euthanasia with a xylazine/ketamine 
injection and cervical dislocation.  Brains were rapidly dissected into ipsilateral and contralateral 
hemispheres. The hemispheres were flash frozen in liquid nitrogen and stored at -80°C until 
analysis was performed.  Following a brief thaw, the samples were homogenized in 1 mL of 50% 
trichloroacetic acid and centrifuged (10,000 rpm, 20 min). Supernatant (200 µL) was removed 
and diluted fourfold with ethanol. Samples were distributed into a 96-well optical plate (Nunc 
165305) and scanned on a fluorescent plate reader (620 nm excitation, 680 nm emission; Infinite 
M200, Tecan) to quantify the dye concentrations. Concentrations were based on external 
standards dissolved in the same solvent. 
2.4.  Histochemistry 
2.4.1.  Immunofluorescence. Rats and mice were euthanized with 0.3 ml of ketamine (10 
mg/ml) and xylazine (0.5 mg/ml). Rats were then transcardially perfused with heparin, which 
was followed by fixation with 4% paraformaldehyde (PFA) in 1x PBS. Brains were dissected 
and given serial incubations at 4°C with 4% PFA (24 hr), 1x PBS (24 hr), and 30% sucrose in 1x 
PBS (until brain sank; ~ 2 days). Brains were then sectioned with a cryostat. Sections were 
blocked for 1 hr with 10% normal goat serum/1% bovine serum albumin with 0.1% Triton-X100, 
incubated with primary antibody diluted in blocking buffer (overnight at 4°C), washed with 
PBS-Triton-X100 (0.1%) (3 times; 5 min each), incubated with the species appropriate Alexa 
Fluor-conjugated secondary antibody (Invitrogen, Grand Island, NY) (1:1000 in blocking buffer; 
2 hr at RT). Slides were also stained with Hoechst 33342 (1 µg/ml in blocking buffer, Invitrogen; 
15 min at RT) to visualize nuclei or with NeuroTrace fluorescent Nissl stain (1:300 in blocking 
buffer, Invitrogen; 30 min at RT) to visualize neuronal ribosomes/endoplasmic reticulum. 
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Human samples were additionally treated with Sudan Black (1% in 70% ethanol) for 5 min at RT 
and washed with PBS (3 changes; 3 min each).  
For detection of fluorescent staining, sections were imaged with an upright Nikon 
(Melville, NY) fluorescent microscope using a SPOT digital camera (Sterling Heights, MI) or 
with a Perkin-Elmer Spinning Disc Confocal Imaging System (Waltham, MA) with a Nikon 
Eclipse TE200 Inverted Microscope with Hamamatsu 1394 Orca-ER digital camera.  
Quantification of neurons and axons was accomplished using the Cell Counter plug-in for 
ImageJ (NIH). For quantification in the rat brain, images were acquired with a 20X objective 
(Nikon) of the dorsal motor cortex and the S1 somatosensory cortex forelimb region; both 
regions are contained within the infarct penumbra. For mice, the same penumbral regions were 
imaged/analyzed as well as regions from the secondary somatosensory and the granular insular 
cortex; both constitute the ischemic core. Single blind counts of processes or neurons were made 
in both regions of interest and then pooled for each individual animal. At least three animals 
were used per cohort. For mouse brains, 20X magnification images were taken in the S1 
somatosensory cortex forelimb region and similar counts were made as described below. Counts 
were made for neurofilament light chain (NF-L) positive processes and NeuronalN (NeuN) 
positive cell bodies. Comparisons between groups used the Student’s t-test or ANOVA, p-value: 
0.05. 
2.4.2.  Immunohistochemistry (DAB staining). Human samples were also analyzed with DAB 
staining. Samples were incubated with 0.3% H2O2 for 30min, followed by blocking with 10% 
normal goat serum/1% bovine serum albumin in PBS, and primary antibody incubation diluted in 
blocking buffer overnight at 4°C. After washing with PBS, slides were incubated with a species 
appropriate biotin-conjugated secondary antibody (Vector Laboratories, Burlingame, CA) for 30 
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min at RT. Samples were then incubated with ABC reagent (Vector Laboratories) for 30 min and 
DAB stain for 10 min. Samples were counterstained with hematoxylin, subsequently dehydrated 
with ethanol, and cleared with 2 washes of xylene.  
2.4.3.  Infarct Volume. Twenty-four hours after MCA occlusion, rats and mice were euthanized 
with 0.3 ml of ketamine (10 mg/ml) and xylazine (0.5 mg/ml). Sections were prepared for 
immunohistochemistry (see 2.4.1.) and stained using a hematoxylin-and-eosin kit from American 
MasterTech (#KTHNEPT; Lodi, CA). Infarcted brain tissue was classified as an area of 
hematoxylin negative (pink) tissue in a surrounding background of viable (blue and pink) tissue. 
Serial sections were photographed and projected on tracing paper at a uniform magnification. 
Direct and indirect infarct volumes were calculated from three serial sections. Direct stroke 
volume was expressed as the area of the infarct divided by the area of the ipsilateral hemisphere. 
Indirect stroke volume was expressed as the area of the infarct divided by the area of the 
contralateral hemisphere. Comparisons between groups used the Student’s t-test or ANOVA, p-
value < 0.05  
2.4.4. Bielschowsky Staining (Axons).  Mouse and rat sections were stained with Modified 
Bielschowsky’s Stain (American MasterTech #KTBIE), subsequently dehydrated with 3 changes 
of ethanol, and cleared with 2 washes of xylene.  
 For mice, the numbers of Bielschowsky-positive axon tracts in the striatum were hand 
counted from uncropped images acquired with a 20X objective (Nikon).  
2.5.  Cell culture 
2.5.1.  Hippocampal and Cortical Neurons. Hippocampal neurons from E-18 rat embryos 
were dissected, dispersed in a defined serum free media, and plated on poly-D-lysine coated (0.1 
mg/ml) in 6-well Nunc tissue culture dishes (9.6 cm2/well; Thermo Fisher Scientific). Plates for 
 41 
cortical neurons were also coated with laminin (0.1 µg/ml). The neurons were maintained in a 
serum free environment with Eagle’s MEM and Ham’s F12 (Gibco; Gaithersburg, MD) 
containing glucose (6 mg/ml), insulin (25 µg/ml), putrescine (60 µM), progesterone (20 nM), 
transferrin (100 µg/ml), selenium (30 nM), penicillin (0.5 U/ml), and streptomycin (0.5 µg/ml). 
Glial cells make up less than 2% of the culture. All cells were cultured for 8-10 days before 
treatment.  
2.5.2.  Neuronal Survival Assays. 
4-hydroxynonenal (HNE). To induce caspase-9-mediated death [170], 4-hydroxynonenal (3 
µM; Cayman Chemicals, Ann Arbor, MI) was added to cultures in triplicate with and without 
Pen1-XBIR3 (80 nM). After 1 day of treatment cell number was quantified as previously 
described [170]. Briefly, the cells were lysed in counting buffer, and intact nuclei were counted 
using a hemocytometer. Nuclei of the healthy cells appear bright and have a clearly defined 
nuclear membrane, while nuclei of dead cells disintegrate or appear irregularly shaped. Cell 
counts were performed in triplicate wells and averaged. Survival is relative to control wells. 
Comparisons between groups used the Student’s t-test or ANOVA, p-value: 0.05 
Proneurotrophin. To trigger p75NTR-mediated death, cortical neurons were treated with mouse 
furin-resistant proNGF (ΔproNGF, Alomone Laboratories, Jerusalem, Israel). Cultured rat 
cortical neurons were treated overnight with mouse ΔproNGF (mΔproNGF; 1 ng/ml & 10 
ng/ml).  
Cell viability was assessed as described directly above. For western blotting, culture 
medium was aspirated, and cells were washed once with sterile 1x PBS. Cells were harvested 
with RIPA lysis buffer (Appendix I – Cell Lysis Buffers). 
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2.6.  Materials 
2.6.1.  Antibodies.  
Immunohistochemistry: anti-Tuj1 (Abcam #ab7751, Cambridge, MA), anti-neurofilament-L 
(Cell Signaling #2835, Danvers, MA), anti-GFAP (Thermo Scientific #PA1-10004), anti-full-
length and cleaved caspase-9 (Abcam #ab28131), anti-cleaved caspase-6 (Cell Signaling #9761), 
anti-cleaved caspase-3 (Cell Signaling #9661), anti-CD34 (Dako #M7165, Carpinteria, CA), 
anti-smooth muscle actin (Dako #M0851), and anti-cleaved caspase-7 (MBL #BV-3147-3).  
Western blotting: THE™ anti-His (GenScript #A00186), anti-caspase-6 (BD #556581), anti-
cleaved caspase-6 (Cell Signaling #9761), anti-cleaved caspase-3 (Cell Signaling #9661), anti-
Tau V-20 (Santa Cruz Biotechnology #sc-1996, Santa Cruz, CA), anti-Lamin A/C (MBL 
International #JM-3267-100, Woburn, MA), anti-full-length and cleaved caspase-9 (Abcam 
#ab28131), anti-neurofilament-L (Cell Signaling #2835), anti-microtubule-associated protein 2 
(Sigma-Aldrich #M9942), anti-TauC3 (Santa Cruz #sc-32240), anti-matrix metalloproteinase-9 
(Cell Signaling #3852),  anti-ERK (Santa Cruz #sc-93), and anti-α-tubulin (Abcam #ab7750). 
Receptor Blocking: anti-mouse NGF (Sigma-Aldrich #N6655).  
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Chapter 3.  Initiator Caspases in Stroke Neurodegeneration 
3.1. Introduction 
The activity of individual caspases has not been specifically assayed in the setting of 
stroke. It is not known when caspase activity is initiated during a stroke, and defining the time 
course of caspase activation is important from a mechanistic and a therapeutic perspective. The 
participation of individual caspases in stroke is poorly understood, but it is generally accepted 
that initiator caspases are active first, which leads to effector caspase activation and ultimately to 
cell death. With 11 individual caspases present in the human or rodent brain, specific measures 
are required to understand the caspase pathways initiated by stroke.  
At present, the caspase activity probe biotin-VAD-fmk (bVAD) is the best method for 
determining if caspases are active after a death stimulus. Commercial catalytic inhibitors do not 
provide the specificity that is required to accurately dissect caspase pathways [90, 91]. BVAD is 
an irreversible pan-caspase inhibitor that has been used in cell culture models to measure caspase 
activation following various death stimuli [171-173]. This method was recently adapted for use 
in cultured primary neurons [173]. We now apply it for use in vivo in the CNS. BVAD binds 
irreversibly to all caspases that are active. In other words, if a caspase is active and its active site 
is available, bVAD will bind to it. Once bVAD is bound, it also inhibits that caspase, blocking 
any downstream events. Since bVAD is biotinylated, it can be isolated on streptavidin agarose, 
along with any active caspase that is bound to it. Administration of bVAD prior to induction of 
death will trap active initiator caspases, and the activation of effector caspases will be prevented. 
Thus, bVAD is useful for studying the inceptive events related to caspase activation in stroke.   
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Using bVAD-caspase precipitation, we revealed a previously undefined role for caspase-
9 activity in transient ischemia in adult rodents, and similarly novel role for caspase-8 in neonatal 
stroke (Chapter 3.2.1. and 3.2.5.). 
To determine the functional relevance of caspase-9 activity in stroke pathogenesis, we 
inhibited caspase-9 activity both pre- and post-ischemia.  As stated above, commercial inhibitors 
have limited specificity, so we devised a novel method for modulating caspase activity, based on 
endogenous metazoan caspase-9 inhibitors. Mammals express a family of cell death inhibiting 
proteins known as IAPs or Inhibitors of Apoptosis Proteins. IAPs contain baculoviral IAP repeat 
(BIR) domains, which perform specific functions. One member of this family, X-linked IAP 
(XIAP), is a potent, specific inhibitor of active caspases-9, -3, -7. IAPs are comprised of 
baculoviral IAP repeat (BIR) domains. For XIAP, caspase inhibition specificity is dependent on 
the BIR domains. The BIR3 domain is a specific inhibitor of active caspase-9, while the BIR2 
domain inhibits active caspases-3 and -7 [94]. XBIR3 was linked to the Trojan peptide Pen1 to 
facilitate cellular delivery and administered to the CNS via an intranasal route (. 3.2.3.). The 
efficacy of Pen1-XBIR3 in the prevention of stroke-induced is reported. Moreover, the use of 
intranasal delivery is an exciting development for stroke therapy [174, 175]. Intranasal delivery 
takes advantage of the olfactory and trigeminal pathways to bypass the BBB and directly access 
the cerebral spinal fluid and ventricular system.   
As stated in Chapter 1.1.1. and 1.4., the cerebral vasculature is compromised during 
stroke, which leads to the passive extravasation of fluid into the tissue parenchyma. This process 
is termed cerebral edema. While damage to large bloods vessels results in hemorrhage, edema is 
caused by the breakdown of BBB permeability in capillaries (microvessels).    
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Previous studies have demonstrated that the p75 neurotrophin receptor (p75NTR) death 
pathway activates caspase-9 [55-58, 176], and p75NTR activation by proneurotrophins increases 
edema during cardiac ischemia (Barbara Hempstead personal communication). Based on these 
collective findings, our lab hypothesized that p75NTR activation by proneurotrophins induces 
caspase-9-dependent cerebral edema during transient ischemic stroke.  To explore this potential 
mechanism, we conducted a histological study of the components of the neurovascular unit (i.e., 
pericytes and endothelial cells) along microvessels to assess a possible relationship to edema and 
caspases (expression and activity) (Chapter 3.2.4.).  
 As stated in . 1, matrix metalloproteinases (MMPs) play crucial roles in the maintenance 
of the BBB and are implicated in cerebral edema during stroke. For example, MMP-9 expression 
is increased during ischemia, and MMP-9-null mice develop less edema after ischemia [177, 
178].  MMP-9 is inhibited endogenously by TIMP-1, which has a putative caspase-9 cleavage 
site. In this chapter, we explore the relationship, if any, between caspase activity and MMP-9 in 
transient ischemia (Chapter 3.2.4.).  
3.2. Results 
3.2.1. Measuring Initiator Caspase Activity In Vivo 
To determine which initiator caspases were activated early in stroke, rats were injected 
with 200 nmoles bVAD via convection-enhanced delivery (CED) to the rat striatum. Injections 
were executed immediately prior to transient MCAo (2 hr occlusion), which was followed by 
reperfusion and sacrifice at 1 hour post reperfusion (hpr). The injected region was dissected, and 
bVAD-caspase complexes were isolated on streptavidin-agarose beads and analyzed by western 
blotting. BVAD captured caspase-9 and caspase-8 (Figure 3-1A), which indicates the activation 
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of these initiator caspases as an early event in stroke.  Caspase-1 and caspase-2 were not trapped 























3.2.2.  Temporal Activation of Caspase-9 in Cerebral Ischemia 
While caspase-9 can be isolated with bVAD early in the stroke (1hpr, Figure 3-1A), it is 
still active at 4hpr (Figure 3-1B). Thus, there is extended activation of caspase-9 during stroke. 
This finding is likely indicative of progressive cell death during stroke. In other words, not every 
cell dies at once.  
The caspase-9 antibody that was used for staining recognizes full-length and cleaved 
forms of the protease. Therefore, elevated IHC staining in ischemic samples could be indicative 
of increased caspase-9 expression, increased caspase-9 cleavage into activated forms, or both. 
The input samples for the western blots in Figure 3-1 demonstrate that full-length caspase-9 
expression is not elevated in the ipsilateral versus contralateral hemispheres at 1hpr or 4hpr.  
Thus, positive caspase-9 staining in Figure 3-2 is potentially due to caspase cleavage and the 
binding of antibody to neoepitopes.  
After stroke, there is a detectable increase in caspase-9 immunofluorescence at 4hpr and 
24hpr (Figure 3-2). Caspase-9 co-localized with cleaved forms of effector caspase-6 (cl-C6) in 
processes and soma. In healthy rodent brains, caspase-9 and cl-C6 are not detected by 
immunostaining (Chapter 4 Figure 4-8). The co-localization of caspase-9 and cl-C6 supports a 
mechanism for caspase-9 activating caspase-6 (discussed in Chapter 4). 
Interestingly, active caspase-8 was not isolated at 4hpr by bVAD pulldown (Figure 3-1B; 
densitometry is provided because of considerable background in vehicle samples). This finding 
implies that caspase-8 mediates cell death in the early, but not late, stages of transient ischemia. 
Caspase-1 and caspase-2 were not trapped by bVAD at 4hpr (Figure 3-1D).    
3.2.3. Caspase-9 Inhibitor: Penetratin1-X-linked Inhibitor of Apoptosis Protein-BIR3 
Domain (Pen1-XBIR3) 
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Therapeutic access of compounds to damaged neurons in the brain requires overcoming 
several obstacles including the blood brain barrier (BBB) and the plasma membrane of the 
neuron. To provide intracellular delivery, XIAP-BIR3 was disulfide-linked to Penetratin1, a cell 
permeating peptide [179] (Figure 3-3A). Upon entry into the cell, the reducing environment of 
the cytoplasm breaks the disulfide linkage. This event releases the peptide cargo and allows it to 
act at its target. Functional efficacy of this construct was confirmed using primary hippocampal 
neuron cultures that were subjected to 4-hydroxynonenal (HNE)-mediated death, which is 
dependent on caspase-9 [170]. Treatment of HNE-treated cultures with Pen1-XBIR3 abrogated 
death compared to vehicle treatment alone (Figure 3-3B).   
To ensure that a Pen1-peptide could be delivered to cells, Pen1-XBIR3 was labeled with 
rhodamine and delivered to cortical neurons in culture. After a 30-min incubation, Pen1-XBIR3 
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was clearly present within the soma (Figure 3-3C). Without a cell transduction peptide, 
rhodamine collected on the outside of cells (Figure 3-3C).  
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It is valuable for drug design to understand the stability of a compound in a physiological 
setting. Unfortunately, we could not perform full-fledged half-life studies in cell culture or 
animal models because we were limited by our supply of recombinant XBIR3 peptide. As an 
alternative, we incubated aliquots of Pen1-XBIR3 (3 µl of 36 µM stock) in 50 µl of cortical 
neuron lysate for prescribed periods or time (0 hr, 1 hr, 4 hr, 8 hr, 24 hr, 3 day, 7 day) at 37°C. 
Pen1-XBIR3 is stable in cortical neuron extracts for at least 24 hr (Figure 3-3D).  
To demonstrate peptide delivery in the CNS, Pen1 was linked to a FITC-labeled control 
peptide (termed “hexapeptide”; 6 aa) that was also labeled with FITC. Pen1-hexapeptide was 
delivered directly to the striatum using convection-enhanced delivery (CED). Brains were 
harvested 1 hr after delivery (Figure 3-4). The FITC-hexapeptide entered cells (Figure 3-4 inset) 
and was distributed throughout the ipsilateral hemisphere.  
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CED administration provided proof-of-principle that Pen1-peptide can be delivered into 
the cells in the CNS, but we also utilized a method with greater therapeutic potential: intranasal 
delivery. Intranasal delivery of neurotrophins and other compounds has been demonstrated to 
provide access to the CNS to prevent neurodegeneration in a number of disease models [101] 
including with stroke [174, 175]. This delivery method takes advantage of the olfactory and 
trigeminal pathways to bypass the BBB and directly access the cerebral spinal fluid and 
ventricular system. Given that Pen1-cargo indiscriminately crosses biological membranes, 
systemic administration might result in the cargo being lost in epithelial cells and pericytes as the 
molecule crosses the BBB or entrapment by non-target organs.  
 Until now, proteins and compounds delivered intranasally to the rodent CNS have 
targeted extracellular molecules, such as cell surface receptors. Since we were targeting 
caspases, which are intracellular proteins, we needed a method for transporting cargo across the 
plasma membrane. As shown above (Figures 3-3 & 3-4), Penetratin1 provides intracellular 
uptake of linked peptides. Pen1-XBIR3 was delivered intranasally to rats; brains were sliced 
coronally; and the presence of XBIR3 in the brain was determined by western blotting (Figure 3-
5).  Pen1-XBIR3 was delivered to all slices of the brain, similar to the delivery pattern observed 
with IGF [103].  
The effects of Pen1-XBIR3 on ischemia-induced changes in neuron density were 
assessed by immunostaining for NeuN. Prophylactic intranasal Pen1-XBIR3 provided significant 
protection against neuron loss at 24hpr, (Figure 3-6). Fluorescent Nissl (NeuroTrace) staining of 
neuronal ribosomes/endoplasmic reticula yielded similar results (Figure 3-6).  
We tested whether Pen1-XBIR3 could prevent sensory-motor disability seen in stroke by 
administering either a prophylactic (pre-occlusion) or therapeutic (4hpr) intranasal bolus of 
 52 
vehicle or Pen1-XBIR3. All prophylactic administrations were given immediately prior to the 
occlusion. Rats were assayed with a 24-point neurofunctional scale beginning at 1 day post-
ischemia, with testing every other day for 3 weeks after the ischemic event. Animals treated with 
Pen1-XBIR3, either prophylactically or at 4hpr, exhibited significantly less stroke-related 
disability than their vehicle-treated counterparts (Figure 3-7). Therapeutic protection by Pen1- 
XBIR3 indicates that caspase-9 activation is persistent at least until 4hpr and that this pathway is 
critical for the acute neurodegeneration elicited by stroke.  
3.2.4. Proneurotrophins, Caspase-9, and Cerebral Edema 
Direct stroke volume (infarct area:ipsilateral hemisphere area) at 24hpr, as measured by H&E 
staining, was also reduced in the Pen1-XBIR3 cohort (Figure 3-8; Veh: 55.08 ± 3.546 vs. Pen1-
XBIR3: 38.56 ± 4.749). Direct stroke volume automatically corrects the size of the infarct for its 
level of edema. In contrast, indirect stroke volume (infarct area:contralateral hemisphere area) 
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does not account for the contribution of edema to infarct size. For vehicle-treated animals, 
indirect stroke volume was 65.95 ± 4.933, meaning edema accounts for about an 11% expansion 
in the size of the infarct. For the Pen1-XBIR3 cohort, stroke volume was essentially identical 
between direct and indirect measurements (38.56 ± 4.749 vs. 39.24 ± 6.276). This finding may 
indicate that Pen1-XBIR3 reduces edema during MCAo, in addition to decreasing stroke volume. 
These results show that caspase-9 mediates neuronal death and that intranasally delivered Pen1-
XBIR3 is neuroprotective against stroke. 
Previous studies have demonstrated that the p75 neurotrophin receptor (p75NTR) death 
pathway activates caspase-9 [55-58, 176], and p75NTR activation by proneurotrophins increases 
edema during cardiac ischemia (Barbara Hempstead personal communication). It is possible that 
p75NTR stimulation by proneurotrophins is connected to the progression of edema development 
during stroke. In normal tissue, p75NTR stains small blood vessels and co-localizes with the 
pericyte marker smooth muscle actin (SMA) (Figure 3-9A). Pericytes are contractile cells that 
surround cerebral capillaries and that govern blood brain barrier integrity in healthy and 
pathologic scenarios [45]. At early time points of ischemia (1hpr), p75NTR also co-localized 
with the small vessel endothelial marker CD34 (Figure 3-9B).  Thus, p75NTR is spatially primed 
to induce cell death in brain capillaries.  
Caspase-9 staining is also found in the vasculature during the early stages of stroke (1hpr) 
(Figure 3-9C). In this scenario, caspase-9 co-stains with the endothelial CD34 marker but does 
not overlap with the pericyte marker SMA (Figure 3-9D). The caspase-9 antibody that was used 












Therefore, the rapid increase in caspase-9 staining by 1hpr in ischemic samples could be 
indicative of increased expression, increased cleavage, or both. Akin to cortical tissue (Chapter 4 
Figure 4-8A), vasculature in control animals was negative for capase-9 staining. 
We found that Evans blue extravasation was increased by 4hpr in mice given intranasal 
vehicle (saline) prior to tMCAo (Figure 3-10A). In contrast, intranasal Pen1-XBIR3 treatment of 
mice immediately before occlusion reversed vascular leakage, as measured by Evans blue 
(Figure 3-10A; Ipsilateral: control - 0.6517 ± 0.09159; Veh-4hpr - 1.154 ± 0.0626; Pen1-XBIR3-
4hpr - 0.7378 ± 0.08593; n = 4 per group; units: ng of Evans blue/mL lysate sample). The 
contralateral hemisphere was used as an internal control (Figure 3-10A; Contralateral: control - 
0.5574 ± 0.1481; Veh-4hpr - 0.7191 ± 0.2125; Pen1-XBIR3-4hpr - 0.5435 ± 0.06621; n = 4 per 
group; units: ng of Evans blue/mL lysate sample).  
We hypothesized that p75NTR and caspase-9 mediate edema through the disinhibition of 
MMPs. With this regard, expression of the p75NTR-activator proNGF is induced in stroked 
animals at 12 and 24hpr (Figure 3-10B). When MMP-9 expression was assayed at 24hpr in 
control, vehicle-treated, and Pen1-XBIR3-treated rats, we found that stroke elevated MMP-9 
expression, but Pen1-XBIR3 prevented this induction (Figure 3-10C).   
3.2.5. Caspase-8 in Neonatal Hypoxia-Ischemia 
In collaboration with Dr. Vadim S. Ten (Columbia University), we investigated whether 
initiator caspases are active in the early stages of neonate hypoxia-ischemia. Previous studies 
have demonstrated that neonate Bax-/- mice are resistant to hypoxia-ischemia [46], and broad 
caspase inhibitors are neuroprotective in this model [44]. Akin to Chapter 3.2.1., we used bVAD 





injury prior to hypoxia-ischemia. Caspase-bVAD complexes were extracted 1 hour after 
hypoxia-ischemia.  
In contrast to adult tMCAo, caspase-8 was isolated but not caspase-9 (Figure 3-11). 
Additionally, caspase-2 was not isolated, although genetic ablation of caspase-2 is 
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neuroprotective against hypoxia-ischemia [95, 96]. It is possible that caspase-2 is not activated at 
this early stage. Although caspase-1 was not isolated with bVAD, this inhibitor appears to affect 
the expression level or potentially the processing of this inflammatory caspase (Figure 3-11, 
inputs). It is possible that bVAD inhibits a caspase that modulates caspase-1. Given the role of 
caspase-1 in cytokine production, this finding points to a caspase-caspase-1 regulatory pathway 
for inflammation.  
3.3. Discussion 
It is common practice to use short peptide caspase substrates, such as DEVD for caspase-
3 and IETD for caspase-8, to measure caspase activity. However, these peptides are highly 
promiscuous [91] and can generate misleading data. Biotin-VAD-fmk, an irreversible pan-
caspase inhibitor, provides a reliable measurement of caspase activity, through the biochemical 
pulldown of active caspases, and has been shown to isolate caspases-1, -2 -8 or -9, depending on 
the death stimulus utilized. Originally used to assay caspase activity in cell lines [171], and, more 
recently, in primary neuron cultures [173], we have adapted this procedure for in vivo use in the 
CNS. In the present study, we use this technique to demonstrate that caspase-9 is active early in 
the progression of the infarct (1hpr). Caspase-8 is also active during the earlier stages of adult 
tMCAo and in neonate hypoxia-ischemia.  
Small peptide caspase inhibitors, such as zVAD and DEVD, have been shown to confer 
neuroprotection in rodent models of stroke [89].  These inhibitors, as mentioned above, are not 
specific for individual caspases [91]; therefore, these studies do not specify which caspases are 
most important.  
Given the non-apoptotic functions of caspases in the nervous system, such as with 
caspase-3 and synaptic plasticity [92], indiscriminately blocking the entire caspase family might 
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prove detrimental to stroke recovery.  For example, axon sprouting and regeneration are common 
after ischemic attack and are arguably important for recovery [180]. 
 
Growing evidence supports a role for caspases in synaptic plasticity [92], dendrite 
pruning [181], and axon regeneration in the context of retinal injury [182]. Although a 
relationship between caspases and axon regeneration during stroke has not been investigated, it is 
possible that non-selective caspase inhibition could impair this recovery mechanism.  
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Alternatively, rampant cell death might be needed early in stroke to remove terminal cells 
(i.e., cells past the point-of-no-return), but prolonged apoptotic activity could be unnecessarily 
detrimental. Defining the best windows of treatment is imperative for the success of caspase-
based neuroprotection.  
The extrinsic caspase-8 pathway is clearly activated during the early stages of adult 
tMCAo as well as in neonate hypoxia-ischemia.  A specific caspase-8 inhibitor is required to 
assess the importance of caspase-8 in stroke pathogenesis.  
This chapter details a central role for caspase-9 in stroke pathogenesis and possibly 
ischemic edema. Caspase-9 activity is stimulated early in stroke, and elevated caspase-9 is 
observed in neurons with cl-C6. Thus, we hypothesized that caspase-9 leads to caspase-6 
activation during stroke.  
The findings in this chapter show that intranasal Pen1-XBIR3 is neuroprotective against 
stroke with measurements of short-term (neuron density/stroke volume at 24hpr) and long-term 
(3-week neurobehavioral assay) outcomes. 
The BIR3 domain from XIAP (XBIR3) is a highly specific inhibitor of caspase-9. We 
linked XBIR3 by a reducible disulfide bond to Penetratin1 (Pen1), a transduction peptide that 
efficiently delivers cargo across the plasma membrane [179, 183, 184] to inhibit caspase-9 
activity in cells. The use of a transient disulfide linkage between Pen1 and the cargo peptide 
ensures that the cargo peptide can assume its native functional conformation once it is 
transported into the cell. This method contrasts with cell permeant peptide fusion domains, such 
as TAT, which can lead to non-functional misfolded cargo protein (G. Salvesen, personal 
communication). Prior studies showed that Intraperitoneal delivery of a similar caspase-9 
inhibitor, a fusion protein of PTD-XBIR3-RING (protein transduction domain with XIAP BIR3 
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and RING domains), reduces infarct volume following tMCAo [183, 184], but did not explore 
the downstream mechanisms, which are addressed in the next chapter. 
This chapter outlines the previously unknown contribution of the p75NTR-caspase-9 
pathway in ischemic edema. Inhibiting caspase-9 prevents Evans blue extravasation at 4hpr  
(Figure 3-10) along with the expansion in hemispheric swelling and midline shift at 24hpr 
(Figure 3-8), which signifies a healthier BBB. This is the first demonstration that caspases 
mediate edema during cerebral ischemia. P75NTR and caspase-9 immunofluorescent staining 
were observed in neurovascular cells (endothelial and pericytes) before (with p75NTR) and 
during the early stages  (with p75NTR and caspase-9) of ischemia (Figure 3-9).   Moreover, p75 
expression, as measured by western blot, is increased at 12hpr and 24hpr (Figure 3-10). 
 MMPs are known to cleave substrates in the vascular basal lamina that regulate BBB 
integrity. MMP-2 and MMP-9 have been implicated previously in cerebral edema during stroke 
[139-144], with MMP-9 correlating with a second wave of edema observed approximately 24 hr 
after stroke onset. We show that inhibiting caspase-9 activity reduces MMP-9 expression at 
24hpr, but mechanistic questions remain. 
MMPs are secreted or membrane-bound. Thus, it is unlikely that they directly interact 
with caspase-9, which is restricted to the cytoplasm and is not found in vesicles. It is possible 
that caspase-9, or one of its downstream effector caspases, prevents the transcription of MMP-9. 
The transcriptional promoter region for MMP-9 has been characterized [185]. It is comprised of 
the following binding sites: NF-κB, SP1, PEA3, AP1, TIE, KRE, RCE, and TATA [185]. 
Caspases have been shown to cleave NF-κB p65 [186, 187] and SP1 [186, 188]. Both are 
transcriptional activators, so it is counterintuitive that their cleavage, if it occurs during ischemia, 
would directly lead to an elevation in MMP-9 expression. A brief review of the literature did not 
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yield any publications on other transcription factors that are implicated in MMP-9 expression. 
However, it is possible that cleavage of NF- κB, SP1, or other transcription factors alters the 
function/expression of intermediate(s) that regulate MMP-9.  
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Chapter 4. Effector Caspases in Stroke Neurodegeneration 
4.1. Introduction 
Of the effector caspases, only caspase-3 has been implicated in stroke pathogenesis. 
Genetic knockout of caspase-3 is neuroprotective against stroke (~50% reduction in stroke 
volume) [111, 113]. Until now, the remaining effectors—caspase-6 & caspase-7—have never 
been studied in the setting of cerebral ischemia. Experimental observations during my rotation 
project (Figure 4-1) steered me towards an investigation of caspase-6 function in stroke.   
One of the first indications that caspase-6 is involved with neurodegenerative disease 
came when it was observed that caspase-6 proteolytically cleaves huntingtin in neurons, which is 
required for disease progression in Huntington’s disease [189].  
A role for caspase-6 in axon degeneration is now emerging. Caspase-6 cleaves 
microtubule-associated protein tau, compromising the stability of the cytoskeleton in axons 
[190]. In Alzheimer’s disease (AD), neuropils harbor both caspase-6-cleaved tau and tubulin 
[191, 192]. In neuronal culture models, caspase-6 mediates neuronal death and axonal 
degeneration induced by the activation of the p75 neurotrophin receptor [176, 193] or death 
receptor 6 [127].  
With the latter study, axon degeneration was abundant in dissociated dorsal root ganglion 
(DRG) neurons that were subjected to trophic factor deprivation [127]. The deleterious effects of 
caspase-6, as measured by genetic knockdown, appeared to be restricted to process degeneration 
in this context. In contrast, the neuronal soma remained intact with or without caspase-6.  
The research presented in Chapter 4 demonstrates for the first time that caspase-6 
mediates both neuronal axon and soma loss during ischemia. The temporal activation of caspase-
6 in the stroke penumbra corresponds with the progression of axonal degeneration. Axon 
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degeneration is a major contributor to cell death and might instigate the early stages of apoptosis 
via the removal of target-derived trophic factors [194-196]. In clinical cerebral ischemia, axon 
degeneration is observed as early as 2 days post ischemia [106]; however, the molecular events 
that trigger axon degeneration potentially begin earlier.  
4.2. Results 
4.2.1. Caspase-6 Is Active In Neuronal Processes And Soma Following Stroke 
After identifying which initiator caspases were active early in the stroke, we turned our 
attention towards effector caspases. The bVAD precipitation method, which worked well for 
isolating active initiators, blocks the consequent activation of effectors in vivo. Unlike initiators, 
which can be activated by dimerization without cleavage [43], cleavage of effectors is indicative 
of activation. Thus, we performed immunohistochemical analysis of cleaved effector caspases.  
Rats were subjected to tMCAo, and brains were immunostained for cleaved caspase-6 
(cl-C6) at increasing time points after reperfusion. The penumbral region in the forebrain, 
specifically cortical layers I-IV in the granular insular, somatosensory, dorsal motor cortices 
(Figure 4-1A), revealed a temporal increase in Cl-C6 staining (Figure 4-1B). No cl-C6 
immunostaining was detected in control (non-ischemic) animals. Cleaved caspase-3 was detected 
(discussed in Chapter 4.2.2.), while cleaved caspase-7 was not observed. While there is evidence 
that caspase-3 causes cell death in stroke [111, 113], a role for caspase-6 has never been 
reported.   
By 4 hours post reperfusion (hpr), there was marginal cl-C6 staining in the penumbra, but 
by 12hpr, abundant cl-C6 staining was observed in processes and cell bodies (Figure 4-1B). 
 There was progressive activation of C6 in cell bodies by 24hpr, which continued through 
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3 days post reperfusion (dpr). At 7dpr, cl-C6 was only observed in cell bodies, which appeared 
condensed and might have represented apoptotic bodies.  In wild-type mice subjected to tMCAo, 
the pattern of staining was similar, with cell body and process staining detected at 24hpr and 
3dpr (Figure 4-1C).  This time course neurologically corresponds to both axon degeneration and 
the progression of the infarct, with expansion of the infarct over the first 3 days.   
Co-staining with NeuN showed cl-C6 was present in neurons (Figure 4-2A), whereas 
there was no co-localization with GFAP, a marker for astrocytes (Chapter 4.2.2. Figure 4-3D). 
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To identify whether caspase-6 is cleaved in axons, sections were co-stained for cl-C6 and 
axonal markers (Tuj1 or NF-L). At 24hpr, Tuj1 and cl-C6 were found in single neuron processes 
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(Figure 4-2B). Immunostaining of these processes was not continuous and gaps in the processes 
were positive for cl-C6. Cleaved C6 is also found in axons containing NF-L (Figure 4-2B), with 
similarly cl-C6-filled gaps in the process staining. Assuming that the entire diameter of each 
process was captured in this confocal stack (~20 µm thick, extended focus), one could propose 
that cl-C6 is possibly responsible for the gaps in cytoskeletal staining. Interestingly, previous 
work in AD indicates that caspase-6 cleaves tubulin and tau [191, 192], which may disrupt axon 
stability. Thus, caspase-6 activation might trigger axon degeneration during stroke.  
4.2.2.  Caspase-3 and Neuronal Cell Type Specification 
Immunofluorescent staining for neural cell markers (e.g., astrocytes: GFAP, neurons: 
NeuN) revealed that activated caspase-3 staining was restricted to astrocytes at 12hpr and 24hpr 
(Figure 4-3A). Activated caspase-3 exhibited a nuclear staining pattern, as befitting its apoptotic  
role in chromatin condensation and DNA fragmentation [197].  
Nuclear staining of activated caspase-3 did not associate with the neuron marker NeuN or 
with caspase-9 at 12hpr (Figure 4-3B & C).  Interestingly, axonal caspase-6 did not co-stain with 
GFAP-positive processes (Figure 4-3D).  
A previous study [198] reported that activated caspase-3 (cl-C3) is present in reactive 
astrocytes and microglia during stroke, but cl-C3 co-staining did not correlate with cell death. In 
contrast, the number of reactive astrocytes and microglia increased in stroked regions, 
highlighting a possible non-death function for this caspase in glial cells.  
Astrocyte density was not measured for this dissertation, so no conclusion can be drawn 
from our staining towards this regard. Further investigation of caspase-3 function in astrocytes is 







4.2.3. Caspase-6 Is Enriched In Myelinated Axons 
Immunohistochemistry for activated caspase-6 suggests that this effector is preferentially 
expressed in the axonal compartment. Thus, we performed a neurochemical isolation of 
myelinated axons from control and ischemic rat brains [34]. This sucrose-based technique yields 
three fractions: 1) myelinated axons; 2) a soluble layer with cytosolic proteins; and 3) a pellet 
fraction with nuclei, unmyelinated axons, and insoluble proteins (Figure 4-4). The pellet fraction 
was not analyzed.   
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Somatodendritic microtubule-associated protein 2 (MAP-2) [199] and axonal 
neurofilament light chain (NF-L) [200] fractionate into their predicted compartments (Figure 4-4, 
top and second panels). Caspase-9 is uniformly expressed in both cell bodies and axons (Figure 
4-4, third panel), which agrees with our immunohistochemistry data (Chapter 3 Figure 3-2).  
Full-length caspase-6 and caspase-3 (Figure 4-4) were present in the cell body fraction, 
and the expression of full-length caspase-6 declined during ischemia in the cell body fraction. 
Activated caspase-6 (Figure 4-4, sixth panel) is induced in the axons over the course of the 24 
hours that follow ischemia. This biochemical data supports the concept that caspase-6 activity is 
compartmentalized within axons during ischemia.  
4.2.4. Genetic Knockout Of Caspase-6 Is Neuroprotective 
Next, we examined if caspase-6 inhibition is sufficient for neuroprotection against stroke 
using caspase-6-null mice (caspase-6-/-) [155]. We subjected wild-type and caspase-6-/- mice to 
tMCAo, and caspase-6-/- mice (Figure 4-5A) showed significantly better neurological function at 
24hpr compared to wild-type mice, based on a 28-point exam that measured neurofunctional 
behavior [166] (wild-type: 19.21 ± 1.931, n=14 vs. caspase-6-/-: 12.64 ± 1.525, n=14). H&E 
staining showed a significant difference in infarct volume at 24hpr (wild-type: 61.56 ± 2.853, 
n=3; caspase-6-/-: 45.37 ± 1.482, n=4), which was commensurate with the significant difference 
in neurofunction.   
To determine whether neurofunctional retention was related to the preservation of the 
neuronal soma and axons, we quantified the density of these structures. Wild-type mice 
subjected to 1hr tMCAo showed a 47% decrease in neuronal number compared to non-stroked 
wild-type mice at 24hpr, and this decrease was partially rescued in caspase-6-/- mice (Figure 4-


























C6-/--stroke: 225.0 ± 8.114). Additionally, wild-type mice subjected to tMCAo had fewer NF-L-
positive processes compared to caspase-6-/- mice (Figure 4-6A; 47.67 ± 7.219, n=3 vs. 70.00 ± 
4.916, n=4). Processes from wild-type mice were shorter and exhibited more fragmented NF-L 
staining, suggestive of axon degeneration. Tau is a putative axonal substrate for caspase-6 with 
potential cleavage sites in the N-terminal and C-terminal regions of tau [190, 192].   
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Analysis with an antibody specific to the C-terminal region of tau revealed that caspase-
6-/- brains retained more intact tau than wild-type brains at 24hpr (Figure 4-6B, densitometry: 
0.7216 ± 0.03246 vs. 1.154 ± 0.08655, n=2, mean ± STD).  This finding suggests that caspase-6 
reduces tau levels during stroke. This loss of tau may lead to microtubule instability and the loss 
of process integrity.  
4.2.5. Caspase-6 Is Activated In Human Stroke 
Post-mortem brain tissue from patients who died following ischemic stroke was 
immunostained for cl-C6. Columbia University’s Brain Bank provided human brain samples; 
details on when the ischemic event occurred relative to fixation and slide preparation were not 
provided. DAB imaging (Figure 4-7A) of cl-C6 immunostaining showed cell bodies and 
processes in the infarcted tissue, and NF-L staining of adjacent sections showed a decrease in 
process density.  Using immunofluorescence, we found that cl-C6 immunostaining co-localized 
with a marker for axons (Figure 4-7B).  Cl-C6 was found in a process in the ischemic tissue, and 
the pattern of co-localization with Tuj1 was very similar to that observed in the rodent models of 
ischemia.  
4.2.6. Caspase-9 Activates Caspase-6 During Ischemia 
To determine unequivocally if caspase-9 was activating caspase-6 in vivo, we tested 
whether caspase-9 inhibition could reduce caspase-6 activation.  Pen1-XBIR3 was delivered to 
the striatum 1 hr prior to tMCAo using CED. Animals were harvested at 24hpr, and brain 
sections were immunostained for caspase-9 and cl-C6. Pen1-XBIR3 completely inhibited the 
appearance of cl-C6 in cell bodies and axons (Figure 4-8). Co-staining of caspase-9 and cleaved 
caspas-6 during ischemia was consistently observed for the duration of this project, and it was 
recorded as early as at 4hpr (Chapter 3 Figure 3-2). Thus, caspase-9 activity is necessary for 
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activation of caspase-6 in neuronal soma and processes following a transient ischemic event in 
rats. 
The preceding findings demonstrate that intraparenchymal delivery of Pen1-XBIR3 
prevents activation of caspase-6. To determine if intranasal delivery of Pen1-XBIR3 also altered 
caspase-6 activity resulting from stroke, animals were treated 1hr prior to tMCAo with Pen1-
XBIR3 and harvested at the indicated times of reperfusion.  Brains were analyzed for the 
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expression of activated caspase-6 at 12 and 24hpr.  Intranasal Pen1-XBIR3 significantly reduced 
caspase-6 activation. At 12hpr, there was a trend towards a reduction of caspase-6 activation in  
processes (Figure 4-9A; Vehicle: 144.0±28.50 vs. Pen1-XBIR3: 102.7±23.15). By 24hpr, the 
reduction was significant (Figure 4-9A; Vehicle: 109.7±12.73 vs. Pen1-XBIR3: 57.33±10.04) 
compared to rats treated with saline. Therefore, caspase-9 inhibition using this delivery technique 
reduced caspase-6 activation. Interestingly, cl-C6 levels at 24hpr inversely correlated with a 
reduction in NF-L density (Figure 4-9B; Vehicle-24hpr: 138.0±9.074 vs. Pen1-XBIR3-24hpr: 
213.7±11.84). 
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Cleaved caspase-3 was also observed in nuclei after 4hpr. At 24hpr, Pen1-XBIR3 did not 
alter the presence of cleaved caspase-3 (Vehicle: 89.33±2.333 vs. Pen1-XBIR3: 81.67±7.055). It 





The last two chapters detail an unbiased approach for identifying caspases that are critical 
for neurodegeneration in cerebral ischemia. Our data show that caspases-6 and -9 are regulators 
of neurodegeneration in cerebral ischemia. We have used active caspase trapping and identified 
caspase-9 as an early stage mediator of cell death in stroke that also promotes caspase-6 
activation. We show that caspase-6 is activated in axons, supporting its role in axon degeneration 
during neuronal death [127]. Inhibiting these caspases, either through peptide inhibition of 
caspase-9 or genetic knockout of caspase-6, reduced stroke injury and improved sensorimotor 
outcomes, providing sustained functional neuroprotection out to 3 weeks post-ischemia. 
Two different strategies were employed to deliver Pen1-XBIR3 to the brain. Convection-
enhanced delivery (CED) provided direct delivery to the region of the infarct and completely 
abrogated the activation of caspase-6 in neuronal soma and processes. Therefore, caspase-9 
activity regulates caspase-6 activity in stroke.  
From a therapeutic perspective, intranasal delivery is a very attractive treatment strategy 
for CNS disorders as it provides direct, non-invasive, access to the brain via the olfactory 
pathway. Intranasal delivery combined with the cell permeant peptide Penetratin1 provides 
intracellular delivery to the CNS.  
In the present study, intranasal delivery of Pen1-XBIR3 inhibited caspase-6 activation, 
reduced axon degeneration and was neuroprotective. Pen1-XBIR3-mediated neuroprotection was 
substantial even 3 weeks after the initial insult.  
Our data reveal that caspase-6 activation corresponds to axon degeneration in stroke and 
provide insights into how this process occurs during ischemia. Since caspase-6 activation is 
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relatively delayed following ischemic onset, efficacious inhibition of caspase-6 in stroke may 
provide functional neuroprotection and be a valuable therapeutic strategy for cerebral ischemia. 
Previous investigations have employed genetic strategies of caspase inhibition to 
delineate the post-ischemic function of both initiator and effector caspase activation.  Of the 
initiator caspases, caspase-1-null mice and mice expressing a caspase-1 dominant negative 
transgene are partially protected from transient Middle Cerebral Artery occlusion (tMCAo) [48, 
110]. Caspase-2 null mice do not exhibit neuroprotection [201]. Deletion of caspase-8 or -9 is 
embryonic lethal; thus, mice lacking these caspases have not been studied in tMCAo. Of the 
three effector caspases (3, 6, 7), only caspase-3 has been studied extensively in stroke [89, 111].  
Caspase-3-null mice are protected from tMCAo, showing a critical role for this caspase [113].  
However, caspase-3 gene deletion does not lead to complete protection from stroke. Thus, other 
effector caspases (or non-caspase death mechanism) might also factor into stroke 
neurodegeneration. 
Moreover, our data and a recent study revealed that caspase-3 is induced in non-apoptotic 
glial cells (astrocytes and microglia) during stroke [198]. Astrocytes provide biochemical, 
nutritive, and metabolic support for neurons, while microglia are brain-resident macrophages. 
Both cell types can regulate neuron survival; thus, the non-apoptotic role of caspase-3 in glial 
function requires further exploration.  
Two studies have proposed that caspase-9 does not directly cleave caspase-6 and that an 
intermediate, likely caspase-3, is required for activation [34, 202]. However, both of these 
studies used in vitro conditions to measure caspase activation. We did not observe cleaved 
caspase-3 in mouse or rat axons during stroke. Further investigation is required to determine if 
caspase-9 can directly cleave caspase-6 in vivo, or whether another caspase acts as an 
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intermediary. Pen1-based inhibitors for the remaining members of the caspase family, if suitable 
ones can be generated, would be very useful in this regard. 
In Chapter 4, we demonstrate that genetic ablation of caspase-6 provides neuroprotection 
at the structural and functional levels against stroke. Caspase-6 can cleave tau, affecting its 
ability to stabilize microtubules [190], and caspase-6-mediated cleavage of tau may play a role in 
AD pathogenesis [191, 192]. In our models of cerebral ischemia, active caspase-6 co-localized 
with axonal markers, which suggests that caspase-6 causes degeneration of neuronal axons in 
this disease model.  Although present in the same process, some axonal regions with active 
caspase-6 lacked the process marker, suggesting that caspase-6 was either cleaving the marker or 
leading to its destabilization. In support of this function for caspase-6 in stroke, we have 
observed a reduction in tau in wild-type mice subjected to tMCAo relative to caspase-6-/- mice. 
Further proteomic analysis of tissue lysate from infarcted brains from caspase-6-/- and wild-type 
mice could be used to reveal a broader spectrum of proteins cleaved by caspase-6 during stroke, 
potentially many that regulate axon stability.  
One study of dissociated DRG neurons subjected to trophic factor deprivation reported 
that caspase-6 apoptotic process are initially restricted to the axon, and are immediately required 
for the breakdown of the neuronal soma [127].  We found that caspase-6 mediates both process 
degeneration and neuronal death during ischemia (Figure 4-5 & 4-6). The temporal activation of 
caspase-6 in the stroke penumbra corresponds with the progression of axonal degeneration. For 
other forms of neurodegeneration, axon degeneration is a major contributor to cell death and may 
instigate death via the removal of target-derived trophic factors [194-196]. In these instances, 
axon degeneration preceded cell death. In clinical cases of cerebral ischemia, axon degeneration 
is observed as early as 2 days post ischemia [106]; however, the molecular events triggering 
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axon degeneration may begin earlier. In the penumbral region, we find that axon loss preceded 
neuronal loss, which suggests that axon degeneration precedes neuronal loss following an 
ischemic event.   
Our collective results indicate that the caspase-9/caspase-6 pathway is an excellent target 
for stroke therapy.  This pathway is active in the neurons and is responsible for a significant 
amount of axon loss and neuron death after ischemia.  Moreover, the temporal course of 
activation (present over the first 24 hr) provides a large clinical window for treatment. 
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Chapter 5. Developing A Caspase-6 Inhibitor For in vivo Use 
5.1. Introduction 
Currently, there are no specific caspase-6 inhibitors. Synthetic molecular 
substrates/inhibitors have been generated based on canonical caspase cleavage motifs (i.e. for 
caspase-3: DEVD or for caspase-6: VEID), but these substrates/inhibitors are highly 
promiscuous [91] and not suitable for specific inhibition in vivo. 
 Our collaborator Guy Salvesen has generated expression vectors containing wild-type 
and catalytic dominant negative constructs for caspase-3, -6, -7, and -9 [168]. These recombinant 
proteins contain a 6xHIS-tag; therefore, they can be isolated on Ni2+ resin. We have purified the 
catalytic dominant negative for caspase-6 (C6DN; Cys285Ala) as well as its wild-type active 
partner [168]. Catalytic dominant negatives have been successfully used to inhibit caspase-1 
activity [34, 110, 118]. 
 Caspase-6, an effector caspase, is a dimer zymogen that is activated by cleavage at 
Asp162 and Asp193. Normally, caspase-6 activation is measured by assessing cleavage, since 
there are no endogenous inhibitors of caspase-6. However, antibodies for cleaved caspases do 
not recognize the active site of the caspase, but rather the neoepitope generated by caspase 
cleavage at Asp162 and Asp193.  
In theory, there are two ways that C6DN could inhibit wild-type C6. One is where a 
monomer of C6DN forms a zymogen with a wild-type C6 monomer. Upon cleavage by upstream 
caspases, this hybrid zymogen will be unable to form a functional active site 
 Caspase-6 mediates axon and neuron degeneration [127, 191-193]. To assay the 
inhibitory capacity of C6DN, I utilized a model where active caspase-6 is abundant and 
contributes to cell death. In this model, cortical neurons were treated with mutant, furin-resistant 
 84 
proNGF (ΔproNGF). Proneurotrophins and mature neurotrophins are potent activators of the p75 
neurotrophin receptor (p75NTR). Following neurotrophin (pro or mature) binding, p75NTR 
activation can trigger neuronal apoptosis and axon pruning. P75NTR can also form a complex 
with sortilin after binding to proneurotrophins, which signals apoptosis [60, 203, 204]. Previous 
research from our lab and others shows that p75NTR activation induces caspase-6 activity and 
hippocampal cell death [205]. 
 As proneurotrophins are quickly processed by furin proteases [148], mutated furin-
resistant forms of proNGF were used for this study. Both wild-type and furin-resistant 
proneurotrophins are potent activators of p75NTR that signal cell death [148, 206].   
 Neurotrophin withdrawal also causes neuron death and axon degeneration, which was 
recently shown to be caspase-6 dependent [126, 127]. Nikolaev et al. 2009 monitored this 
process in microfluidic chambers [207], which allows for separate treatment conditions for 
neurons and axons [127]. Local NGF withdrawal at axon tips caused caspase-6-dependent axon 
degeneration. 
5.2. Results 
5.2.1. Use in Neuronal Cultures Models of Cell Death 
To stimulate p75NTR, we treated cultured rat cortical neurons with mouse ΔproNGF 
(mΔproNGF ; 1ng/ml & 10ng/ml) overnight, which induced the cleavage/activation of caspase-6 
(Figure 5-1A) and cell death (Figure 5-1B). Full-length caspase-6 was also increased. Thus, 
neurotrophins induce caspase-6 activation in cortical neurons, akin to previous observations with 
hippocampal neurons [205].  
The cleavage of caspase-6-specific substrates was analyzed. Microtubule-associated 
protein tau is selectively processed by effector caspase-3 and caspase-6 [190]. For western 
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blotting assays to measure caspase-6 activation, antibodies to that target the tau caspase cleavage 
site (anti-TauC3) were used. MΔproNGF induced caspase-mediated tau cleavage (Figure 5-1A) 
as well as cleavage of lamin A/C, a well-established substrate of caspase-6 [202].  
Caspase-6 catalytic dominant negative (C6DN; C285A) was isolated and purified as 
described previously [168]. To facilitate intracellular uptake of C6DN, this peptide was 
disulfide-linked to Penetratin1 [179].  Upon entry into the cell, the disulfide linkage is broken by 
the reducing environment of the cytoplasm, which allows the peptide cargo to execute its 
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function. We have successfully used this technique to deliver XBIR3 to neurons (see [1] and 
Chapters 3 & 4). C6DN can be linked to Pen1, as visualized by a shift in the molecular weight of 
caspase-6 (Figure 5-2A), and deposited into cells (Figure 5-2B). 
Along with the regulation of caspase-6 substrate cleavage, we assayed whether Pen1-
C6DN can prevent p75NTR-mediated cell death. Cortical neurons were treated overnight with 
mΔproNGF. Vehicle or Pen1-C6DN was given prior to neurotrophin treatment. Pen1-C6DN 
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prevented the cleavage of tau (Figure 5-3A), and there was a trend towards reduced neuronal loss 
(Figure 5-3B). 
 5.2.2. Use in Cerebral Ischemia 
Male C57BL/6 mice (2-3 months old; >25g) were anesthetized using isoflurane (2%) 
delivered via an anesthesia mask.  
Pen1-C6DN (31.9 µM) was delivered by administering 2 µl drops to alternating nares 
every minute for 10 min (20 µl total delivered) [103]. Intranasal treatment was performed prior 
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to 1hr transient Middle Cerebral Artery occlusion [157, 158]. Saline was used as a negative 
control. Brains were harvested for western blotting.  
Neuronal death was ameliorated by Pen1-C6DN.  Neuron density was quantified by 
staining brain sections with the neuron marker NeuN and performing hand counts of fluorescent 
images (20x magnification field of view). In the ischemic core, vehicle-treated groups exhibited 
a 48% reduction in neuron density in the ipsilateral hemisphere relative to the contralateral 
hemisphere (85.88 ± 10.36 vs. 165.6 ± 4.903; p < 0.001) (Figure 5-4A). In comparison, neuron 
loss in Pen1-C6DN mice was only 21% (117.9 ± 10.67 vs. 149.8 ± 7.2180). Vehicle versus 
Pen1-C6DN measurements were significantly different (p < 0.05). A similar pattern was 
observed in the penumbra: Vehicle-ipsi - 122.5 ± 9.943; Vehicle-contra - 174.3 ± 5.978; Pen1-
C6DN-ipsi 151.6 ±11.32; Pen1-C6DN-contra 177.4 ±10.18. 
Microtubule-associated protein tau has been identified as molecular substrate of caspase-
6. We used an antibody that binds to the neoepitope generated by caspase-6 cleavage of tau (anti-
TauC3) to measure caspase-6 inhibition by Pen1-C6DN during apoptosis in vivo. Pen1-C6DN 
reduced the cleavage of tau in both the core and the penumbra at 24hpr (Figure 5-4B). Anti-
alpha-tubulin was used for a loading control. 
Congruent with these biochemical findings, degeneration of axonal tracts in the striatum 
was prevented by treating mice with Pen1-C6DN prior to stroke. Brain sections were stained 
using the Bielschowsky method, which labels neurofilaments. The axon tracts were imaged 
(Figure 5-4C) and counted by hand. A clear demarcation of ischemic injury is apparent (Figure 
5-4C). Fewer axon tracts were observed in the ipsilateral (ipsi) hemisphere in vehicle-treated 
animals relative to Pen1-C6DN-treated animals (93.25 ± 22.5 vs. 178 ± 21.73). Neuron densities 
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in the non-infarcted contralateral (contra) hemispheres were comparable (vehicle-contra: 238.3 ± 
9.05; Pen1-C6DN-contra: 241.7 ± 9.244). 
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5.2.3. Use in Optic Nerve Crush 
 To validate Pen1-C6DN with an alternate in vivo model of axo- and neurodegeneration, 
we collaborated with Dr. Zubair Ahmed at the University of Birmingham, UK. His lab studies 
optic nerve damage, which is a hallmark of ophthalmologic diseases like glaucoma and ocular 
trauma. One exceptional disease model is optic nerve transection, which is characterized by the 
selective loss of retinal ganglion cells (RGCs). RGCs are quantified by retrograde labeling with 
the fluorescent tracer Fluorogold (FG). 
Ocular nerve transection or crush impairs retrograde axonal transport of target-derived 
neurotrophins, which triggers apoptosis. Dr. Ahmed recently demonstrated that ablating caspase-
2 expression rescues RGC cell bodies from this injury, but axons continue to degenerate 
[personal communication and [208].  
Dr. Ahmed administered Pen1-C6DN with caspase-2 siRNA (siCASP2) in an optic nerve 
crush (ONC) model in rats [182].  RGCs were rescued by siCASP2 (Figure 5-5A). Pen1-C6DN 
did not significantly change the number of cell bodies that remained in ONC (Figure 5-5A); 
however, more βIII tubulin-positive axons were present after ONC with Pen1-C6DN co-
treatment (Figure 5-5B). The remaining axons were also longer with Pen1-C6DN co-treatment 
relative to siCASP2-alone.  
When Pen1-C6DN was given without siCASP2 (Figure 5-5C), there was a slight increase 
in soma survival that was not as pronounced as with siCASP2/Pen1-6DN. However, axon 
degeneration was impeded by Pen1-C6DN alone (Figure 5-5D), which showed better efficacy 
than siCASP2 alone (Figure 5-5B vs. 5-5D). Thus, caspase-6 is a critical mediator of axon 





Chapter 5 establishes Pen1-C6DN as a potent caspase-6 inhibitor in 3 models of 
neurodegeneration. Small molecule inhibitors lack the specificity to accurately dissect caspase 
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mechanisms [91], so the prospect of Pen1-C6DN as a first-line caspase-6 inhibitor is valuable 
from an academic perspective.  
For example, one of our collaborators, Dr. Zubair Ahmed, has already found promising 
results with Pen1-C6DN in the setting of optic nerve transection. Our data suggest that caspase-2 
and caspase-6 work synergistically to protect optic axons, but Pen1-C6DN by itself is 
axoprotective as well. 
In Chapter 4, I discussed the delayed nature of caspase-6 activation in cerebral ischemia. 
Depending on the stage of neurodegeneration in stroke, a caspase-6 inhibitor used in isolation, or 
in combination with Pen1-XBIR3, might enhance neuroprotection against this disease.  
Moreover, caspase-6 has been implicated in chronic neuropathologies, like Huntington’s disease 
and Alzheimer’s disease. With Huntington’s disease, caspase-6 is required for the cleavage of 
mutant huntingtin into its toxic form, which leads to the selective destruction of motor neurons.  
Thus, it would be worthwhile to test whether Pen1-C6DN is clinically beneficial in Huntington’s 
disease. However, the use of Pen1-C6DN need not be limited to the context of disease and could 
reveal the physiological functions for caspase-6 in axon biology.  
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Chapter 6. Benchmarks: Conclusions and Future Directions  
This dissertation exposes the vital nature of the intrinsic caspase death pathway in stroke 
neurodegeneration. This chapter will outline this project’s achievements and future prospects. 
6.1.  Surveillance Strategy For in vivo Caspase Activity 
 A number of new techniques for measuring caspase activity in living cells or animal 
models were developed for this project. It has become apparent that older strategies for assessing 
caspase activity (i.e., short peptide inhibitors/substrates) lack the specificity to resolve caspase 
mechanisms [90, 91].  
6.1.1.  Benchmark 1: In vivo Active Caspase Precipitation 
 The biochemical isolation of active caspases from living cells was first performed in the 
research laboratory of Douglas R. Green [171]. They found that active initiator caspases could be 
precipitated from cultured neurons by pretreating the cells with bVAD-fmk (bVAD) prior to an 
apoptotic stimulus. BVAD irreversibly binds to any caspase with an available active site. They 
also reported that active effector caspases could be isolated if bVAD was given after the death 
stimulus, but other labs, including ours, have been unable to replicate this finding.  
 It is now widely accepted that bVAD is an excellent tool for isolating initiator caspases, 
which do not require cleavage for activation and have no other specific measure for activity. 
However, this isolation procedure had never been used in animal models until now.  
Animal models of cerebral ischemia are arguably the most ideal systems for validating 
the bVAD-active caspase precipitation method. First, these models have abundant caspase 
activation. Second, stroke models are highly reproducible, which is important for quantitative 
assessments in biochemical analysis. 
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A surveillance strategy based on combining the caspase precipitation assay for active 
initiators with immunoassays for effector cleavage provides comprehensive in vivo analysis of 
caspase activity during apoptosis. Theoretically, if bVAD is saturated in the injured tissue, it 
should trap all of the initiator caspases that are active during the early stages of a death paradigm. 
For effector caspases, cleavage is easily measured by immunoassays (western blotting; WB) and 
immunohistochemistry (IHC). 
However, this strategy is not without limitations. First, because bVAD irreversibly binds 
caspases, it eliminates any consequent downstream activity. Thus, only incipient events can be 
measured by bVAD. The second issue involves the endogenous inhibitor XIAP and the fact that 
we recommend cleavage to represent caspase-3 or caspase-7 activity. Cleavage of caspases-3 and 
-7, as measured by IHC and WB, would not account for caspase molecules that are possibly 
bound to endogenous XIAP in vivo. XIAP could be bound and inhibiting a cleaved caspase-3 
molecule or a cleaved caspase-7 molecule in vivo, but this interaction would not prevent an 
antibody (for IHC or WB) from recognizing the cleaved caspase after the cell is lysed for 
western blotting or fixed for IHC. XIAP expression is upregulated during stroke, so a windfall 
scenario likely exists with immunoassays and IHC, where active capase-3 (cleaved and not 
bound to XIAP) and activated caspase-3 (cleaved, but bound to XIAP) are both counted as 
active. Although caspase-7 is inhibited by XIAP, it was not detected in our stroke model.  
Endogenous inhibitors have not been reported for caspase-6. Therefore, any conclusions drawn 
for caspase-3 in this study while using our strategy should be viewed with “a grain of salt”. 
XIAP can also inhibit caspase-9, but bVAD-caspase precipitation can only isolate 
caspase-9 molecules with an available active site; i.e., active caspase-9 that is not bound and 
inhibited by XIAP. 
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Overall, combing bVAD precipitation for initiators and immunoassays/IHC for cleaved 
effectors is a valuable strategy for studying caspase activity in vivo. 
6.1.2.  Benchmark 2: Innovations For Intracellular Peptide Delivery To The CNS  
Here, we present another robust partnership: Trojan peptide delivery via the intranasal 
route. 
Trojan peptides—like Penetratin1 (Pen1)—are versatile tools that are ready for 
widespread use in drug delivery. They provide a simple method for manipulating intracellular 
targets. For instance, Pen1 provides rapid entry for siRNAs [179] and peptides (Chapter 3.2.3. & 
Chapter 5.2.1.). Linking peptide cargo to Pen1 is straightforward: overnight incubation at 37°C 
with equimolar ratios between Pen1 and cargo (e.g., XBIR3 or C6DN). With regards to protein 
biologics, our results demonstrate that Trojan peptides can rapidly (<30 min) deliver small and 
large cargo (XBIR3: 16 kDA; C6DN: ~34 kDa). For Pen1, the upper limit for the successful 
intracellular delivery of protein cargo is as much as 100 kDa (Alain Prochiantz, personal 
communication).  
 While Trojan peptides mediate passage across the cell membrane, a method is still 
required for delivering protein biologics to their intended organs. This is especially a challenge 
when targeting the brain, where the blood brain barrier (BBB) acts as strict filter for foreign 
molecules in the peripheral blood circulation.  
 Intranasal delivery utilizes the porous nature of the cribriform plate, located on the roof 
of the nasal cavity, to bypass the BBB. This route permits direct access to the CNS by allowing 
peptides to leak into the CSF/ventricular circulation, which provides diffuse spreading 
throughout the CNS [1, 101, 175].  
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 There are limitations for both Trojan peptides and intranasal delivery. Choosing the 
appropriate Trojan peptide is critical for success. For instance, the highly charged nature of Pen1 
can lead to solubility issues during peptide linkage.  
 HIV-TAT is widely used as a carrier protein. However, TAT is permanently linked to its 
cargo as an expression domain, which can cause protein misfolding or inadvertently block 
interactions between the cargo and target.  
 Fewer restrictions exist for intranasal delivery, although the pH and osmolarity of the 
drug vehicle can affect the permeability of the nasal mucosa [101].  
 Overall, Trojan peptides and intranasal delivery are innovative tools for elucidating 
molecular pathways in vivo.  
6.2.  Caspase Biology 
 Our data show that caspase-9 is an early regulator of neurodegeneration during cerebral 
ischemia. Additionally, we provide the first evidence that caspase-6 regulates axon degeneration 
in stroke.  
6.2.1.  Benchmark 1: The Intrinsic Caspase Pathway In Ischemic Neurodegeneration  
 In Chapter 3, we used an unbiased approach to identify caspases that are activated by 
cerebral ischemia. Our data show that caspase-9 is an early regulator of neurodegeneration in 
cerebral ischemia. In our transient ischemia model, Caspase-9 is highly active during the first 6 
hours of ischemia (2 hr of occlusion + 4hpr). BVAD analysis at further time points is required to 
completely define the window of caspase-9 activity.  
 In Chapter 4, we link caspase-9 function to the activation of effector caspases, namely 
caspase-6. This finding relied upon the use of Pen1-XBIR3, a highly specific, membrane-
permeable inhibitor for caspase-9. Both prophylactic (immediately prior to stroke) and 
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therapeutic (at 4hpr) delivery provided long-term neurofunctional protection from cerebral 
ischemia.  
 We propose that this beneficial outcome was due to a combination of factors. First, Pen1-
XBIR3 prevents neuron loss during the first 24hrs of stroke (at least), which also involves the 
inhibition of caspase-6-mediated axonal degeneration. Second, BBB damage and cerebral edema 
are foiled by Pen1-XBIR3 treatment.  
 Remarkably, only one dose of Pen1-XBIR3 (prophylactic or therapeutic) was needed for 
significant neuroprotection. Future studies should assess the benefits, if any, of multiple dosing. 
Additionally, therapeutic windows of treatment must be defined. The average stroke patient 
reaches the hospital 5.5 hours after the first warning sign [39], but it is common for patients to 
arrive 24 hr after a stroke [209]. Therefore, future translational studies with Pen1-XBIR3 should 
focus on determining its efficacy at different stages of stroke.  
6.2.2.  Benchmark 2: The Intrinsic Caspase Pathway In Ischemic Edema 
 We report that the p75NTR-caspase-9 pathway is implicated in the regulation of BBB 
integrity. P75NTR and caspase-9 are expressed at high levels in the cells that comprise the 
neurovascular unit; i.e., pericytes and endothelial cells. Given that proneurotrophins can 
stimulate death via p75NTR signaling, the neurovascular unit is possibly more susceptible to 
proneurotrophin toxicity. This theory requires further investigation.  
 One possibility is caspase-9 damages the BBB by triggering apoptosis in pericytes and 
endothelial cells. This hypothesis could be tested by measuring the density of both cell types in 
blood vessels during ischemia and by then correlating this assessment with the progression of 
edema. 
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 Alternatively, caspase-9 could modulate the activity of enzymes that breakdown the 
vascular basal lamina during stroke, namely matrix metalloproteinases (MMPs). We observed 
that caspase-9 induces the expression of MMP-9 during stroke (Chapter 3.2.4.). MMP-9 has been 
previously linked to stroke neurodegeneration, specifically through its ability to destabilize the 
BBB and cause edema [210]. MMP expression is precisely regulated, and a number of 
transcription factors regulate MMP-9 expression [185]. Some are known targets of caspase 
cleavage, including NF-κB [186, 187] and SP1 [186, 188], which suggests a regulatory 
mechanism.  
 MMPs have recently been shown to regulate proneurotrophin processing. In rodent 
models of seizure [147] and diabetic retinopathy[150], MMP-7 expression and activity are down-
regulated, which leads to an increase in the levels of extracellular proneurotrophins. In turn, 
proneurotrophins induce further cellular damage via p75NTR signaling in these models. MMP-7 
expression was not measured in this study, but if a similar pattern is observed in stroke, it could 
signal a dynamic regulatory loop between p75NTR signaling, caspase-9 activity, and MMPs.  
The complex interplay between the MMP family, proneurotrophins, neuronal apoptosis, 
and cerebral edema during stroke requires further evaluation and should make for exciting 
research in the years to come.  
6.2.3.  Benchmark 3: Axon Compartmentalization Of Caspase-6 Activity 
 Chapters 4 & 5 demonstrate that caspase-6 and the neuronal axon are intimately 
acquainted. Recent evidence [126, 127] describes a critical role for caspase-6 in axon health, 
which is further substantiated by findings in this project.  
Here, we reveal that caspase-6 is involved with stroke-induced axon degeneration. One 
future direction might investigate how caspase-6 mediates axonal destruction. Substrate analysis 
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could reveal the cytoskeletal molecules that are targeted by caspase-6 during stroke. We have 
already demonstrated that caspase-6 is required for the proteolysis of tau during ischemia 
(Chapters 4 and 5). Moreover, staining for cleaved caspase-6 fills axonal regions where 
cytoskeletal staining is absent (Chapter 4). .  
 Is caspase-6 always required for axon degeneration or are there unique scenarios for its 
involvement? The caspase-6 inhibitor developed in this study (Pen1-C6DN) is based on a 
catalytic dominant negative and provides a new tool for answering this question in other models 
of axon degeneration. Indeed, Pen1-C6DN has already demonstrated efficacy in models of ocular 
nerve degeneration, as conducted by our collaborator Dr. Zubair Ahmed (Chapter 5).   
6.3.  Closing Statement 
 This dissertation emphasizes the critical role of caspases in stroke neurodegeneration. 
Given the myriad roles for caspases in stroke neurodegeneration, it is surprising that direct 
caspase inhibition has never been explored in clinical trials.  
We have demonstrated that caspase-based neuroprotection strategies are effective in 
model systems of stroke. The innovations presented herein highlight new avenues for stroke 
therapy and new techniques for the dissection of apoptotic pathways.  
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Appendices. Detailed Protocols 
Appendix I. Cell Lysis Buffers 
 
RIPA Buffer 
150 mM  Sodium Chloride 
1.0%   NP-40 or Triton X-100 
0.5%   Sodium Deoxycholate 
0.1%   SDS (sodium dodecyl sulphate) 
50 mM  Tris, pH 7.4 
 
CHAPS Buffer  
150 mM  KCl 
50 mM  HEPES 




10%   Glycerol 
150 mM  NaCl 
0.2%   NP-40 
20 mM  Tris-HCl (pH 7.3) 
 
4x Laemmli Buffer (SDS Sample Buffer) 
8%   SDS 
40%   glycerol 
240 mM  Tris, pH 6.8 
0.04%   bromophenol blue 
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Appendix II. Active Caspase Precipitation 
 
Protocol 1. With CHAPS Lysis Buffer 
bVAD administered prior to stroke by clysis (CED) injection. 
 
 
Materials & Solutions: 
a. CHAPS Buffer (pH 7.4) 
- 150 mM KCl 
- 50 mM HEPES 
- 0.1% CHAPS 
 
b. Roche Protease Inhibitor tablet or equivalent. 
c. CHAPS w/o protease inhibitors (50 ml) 
d. CHAPS w/ protease inhibitors (10 ml) 
e. Plain agarose beads (GE Life Science# 17-0120-01) 
f. Streptavidin-agarose beads (Invitrogen# SA100-04) 
g. 1x Laemmli Sample Buffer without BME (100-200 ml) 
 
Tissue Preparation: 
1. Lyse tissue with pestle and 200 ml CHAPS Buffer w/ protease inhibitors 
a. Incubate on ice for 15 min 
b. Transfer 75% of the lysate to a new tube (sol. fraction) 
c. Label remaining 25% as whole cell lysate (WCL) and freeze at -20 °C 
 
2. Isolate soluble fraction by centrifugation @ 13,000 rpm for 10 min 
a. Transfer supernatant to a new tube 
b. Measure protein concentration w/ Bio-Rad Bradford assay 
 
Pre-clearing the lysate: 
3. Transfer 30 ml of agarose beads into a fresh 0.5-ml microfuge tube. 
a. Use a cut tip 
 
4. Wash beads with 300 ml cold CHAPS Buffer w/o protease inhibitors; Centrifuge @ 
7,000 rpm for 3 min 4 °C; Aspirate/Discard supernatant 
a. Repeat 2x 
b. After 3rd spin, aspirate as much CHAPS Buffer as possible without removing 
beads. 
 
5. Apply 150 mg of protein sample to washed agarose beads 
a. Fill to 300 ml with CHAPS Buffer w/ protease inhibitors 
b. Rotate @ 4 °C for 1.0 hr 
 
6. Centrifuge pre-clear @ 7,000 rpm for 5 min @ 4 °C 
a. Transfer pre-cleared lysate with a 200 ml pipette to pre-washed Streptavidin-
agarose beads (see below) 
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b.  Discard pre-clear Sepharose beads 
 
bVAD isolation 
7. Transfer 30 ml of Streptavidin-agarose beads into a fresh 500 ml microfuge tube. 
 
8. Wash beads with 300 ml cold CHAPS Buffer w/o protease inhibitors; Centrifuge @ 
7,000 rpm for 3 min @ 4 °C; Aspirate/Discard supernatant 
a. Repeat 2x 
b. After 3rd spin, aspirate as much CHAPS Buffer as possible without removing 
beads. 
 
9. Apply pre-cleared lysate (from above) to washed Streptavidin-agarose beads 
a. Rotate at 4 °C overnight 
 
10. Centrifuge sample @ 7,000 rpm for 5 min @ 4 °C 
a. Aspirate supernatant 
 
11. Wash beads with 300 ml cold CHAPS Buffer w/o protease inhibitors; Centrifuge sample 
@ 5,000 rpm for 5 min @ 4 °C; Aspirate/discard supernatant 
a. Repeat 14x 
b. After the final wash remove as much CHAPS Buffer as possible with a 10 ml 
pipette 
 
12. Add 25 ml of 1X Laemmli Sample Buffer w/o BME to beads 
a. Boil for 5 min in water bath 
b. Centrifuge sample @ 14,000 rpm for 10 min 
 
13. Transfer supernatant to a fresh 500 ml tube  
a. Store at -20 °C until ready to run on SDS-PAGE 
b. On the day of electrophoresis, add 5% BME and boil for 5 min in water bath 




Protocol 2. With bVAD Lysis Buffer 
bVAD administered prior to lysis (i.e. clysis). 
 
Materials & Solutions: 
a. bVAD Lysis Buffer[211] 
- 10% Glycerol 
- 150 mM NaCl 
- 0.2% NP-40 
- 20 mM Tris-HCl (pH 7.3) 
- Roche Protease Inhibitor tablet or equivalent. 
 
b. bVAD lysis buffer w/o protease inhibitors (50 ml) 
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c. Plain Agarose Resin (GE Life Science# 17-0120-01) 
 
d. Streptavidin Agarose Resin (Invitrogen# SA100-04) or NeutrAvidin Agarose Resin (Pierce 
#29200) 
 
e. 1x Laemmli Sample Buffer without reducing agent (100-200 ml) 
 
Tissue Preparation: 
1. Lyse tissue with pestle and 200 ml bVAD LYSIS Buffer w/ protease inhibitors 
a. Incubate on ice for 15 min 
 
2. Isolate soluble fraction by centrifugation @ 13,000 rpm for 10 min 
a. Transfer supernatant to a new tube 
i. Discard pellet 
b. Measure protein concentration w/ Bio-Rad Bradford assay 
 
Pre-clearing the lysate: 
3. Transfer 40 ml of Plain Agarose Resin into a fresh 0.5-ml microfuge tube. 
a. Use a cut tip 
 
4. Wash beads with 300 ml cold bVAD Lysis Buffer w/o protease inhibitors; Centrifuge @ 
7,000 rpm for 3 min 4 °C; Aspirate/Discard supernatant 
a. Repeat 2x 
b. After 3rd spin, aspirate as much bVAD Lysis Buffer as possible without removing 
beads. 
 
5. Apply 100 - 120 mg of sample protein to washed agarose beads 
a. Fill to 300 ml with bVAD Lysis Buffer w/ protease inhibitors 
b. Rotate @ 4 °C for 1.0 hr 
 
6. Centrifuge pre-clear @ 7,000 rpm for 5 min @ 4 °C 
a. Transfer pre-cleared lysate with a 200 ml pipette to pre-washed Streptavidin-
agarose beads (see below) 
b.  Discard pre-clear Sepharose beads 
 
bVAD isolation 
7. Transfer 40 ml of Streptavidin-agarose beads into a fresh 500 ml microfuge tube. 
 
8. Wash beads with 300 ml cold bVAD Lysis Buffer w/o protease inhibitors; Centrifuge @ 
7,000 rpm for 3 min @ 4 °C; Aspirate/Discard supernatant 
a. Repeat 2x 
b. After 3rd spin, aspirate as much bVAD Lysis Buffer as possible without removing 
beads. 
 
9. Apply pre-cleared lysate (from above) to washed Streptavidin-agarose beads 
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a. Rotate at 4 °C overnight 
 
10. Centrifuge sample @ 7,000 rpm for 3 min @ 4 °C 
a. Aspirate supernatant 
 
11. Wash beads with 300 ml cold bVAD Lysis Buffer w/o protease inhibitors; Centrifuge 
sample @ 7,000 rpm for 5 min @ 4 °C; Aspirate/Discard supernatant 
a. Repeat 14x 
b. After the final wash remove as much bVAD Lysis Buffer as possible with a 10 ml 
pipette 
 
12. Add 25 ml of 1X Laemmli Sample Buffer w/o BME to beads 
a. Boil for 5 min in water bath 
b. Centrifuge sample @ 14,000 rpm for 10 min 
 
13. Transfer supernatant to a fresh 500 ml tube  
a. Store at -20 °C until ready to run on SDS-PAGE 
b. On the day of electrophoresis, add 5% BME and boil for 5 min in water bath 




Appendix III. Axon Flotation 




Isolation Buffer (Buffer A) pH 6.6 
100 mM  NaCl (58.44 g/mol) 
10 mM  phosphate buffer (0.0964% NaH2PO4-H2O & 0.0808% Na2HPO4-7H2O) 
5 mM   EDTA (372.24 g/mol) (from 0.5 M EDTA stock solution) 
0.85 M  sucrose (342.30 g/mol) 
 
Demyelination Buffer  (Buffer B) pH 6.6 
 100 mM  NaCl 
 10 mM  phosphate buffer 
 5 mM   EDTA 
 1%   Triton-X 
 
Wash Buffer (Buffer C) pH 6.6 
 100 mM  NaCl 
 10 mM  phosphate buffer 
 5 mM   EDTA 
 
Dissection: 
1. After brain has been removed from skull/meninges, place brain in brain block 
2. From bregma, place one razor 3 mm anterior and another razor 1 mm posterior (4 mm 
brain section 
3. Carefully separate striatum, white matter tracts, and cortical matter 
a. Place in 1.5 ml Eppendorf tube and flash freeze with liquid nitrogen 




1. Place dissected piece into Dounce homogenizer. 
2. Add 500 ml of Buffer A and gently homogenize 
a. Wash homogenizer & pestle with 70% Ethanol followed by H2O between each 
sample. 
3. Centrifuge samples @ 10,000 x g for 15 min 
a. Transfer Myelin float (200 µl) to a new tube  
b. Transfer the remaining soluble fraction to a new tube 
i. Label “sol. frac.” 
ii. This will be the inputs for western blotting 
iii. Optional: Save the pellet fraction (label pellet) 
1. Contains unmyelinated axons/nuclei/insoluble proteins 
 
4. Add 500 ml of Buffer A and repeat homogenization with myelin fraction in Dounce 
homogenizer 
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a. Centrifuge samples @ 10,000 x g for 15 min 
b. Transfer myelin float (200 µl) to new tube 
c. Do not save sol. frac or pellet  
d. Repeat step 4 two more times 
 
Demyelination and Washing: 
 
5. Resuspend myelin float w/ 500 ml Buffer B 
a. Homogenize with Dounce homogenizer 
 
6. Demyelinate by placing tube in rocker for 1hr at 4 °C 
 
7. Pellet axoplasm proteins w/ 10,000 x g for 15 min 
 
8. Remove as much supernatant as possible without disturbing the white pellet. 
 
9. Wash and Pellet 3x with 500 ml Buffer C 
a. Pellet: Centrifuge at 10,000 x g for 15 min 
 
10.  Resuspend axons in 25 ml RIPA buffer with Roche protease inhibitors 
 
11. Measure Protein Concentration and run SDS-PAGE 
 
 
 
